Posts by acn:

CITIC Telecom CPC Wins Outstanding Award at 2025 Hong Kong Sustainable Development Innovation and Technology Awards

HONG KONG, Mar 10, 2025 - (ACN Newswire via SeaPRwire.com) - CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is pleased to announce that it has honored with the outstanding award in the Green Supply Chain Innovation and Technology category at the 2025 Hong Kong Sustainable Development Innovation & Technology Awards. The award recognizes CITIC Telecom CPC’s groundbreaking solution, AI Analytics, for its transformative impact on sustainable supply chain management.CITIC Telecom CPC Wins Outstanding Award at2025 Hong Kong Sustainable Development Innovation and Technology Awards forGreen Supply Chain Innovation and TechnologyThe Hong Kong Sustainable Development Innovation and Technology Awards celebrate organizations and individuals who have demonstrated exceptional innovation and commitment to advancing sustainable development. CITIC Telecom CPC’s AI Analytics stood out for its ability to integrate advanced artificial intelligence (AI) and machine learning into supply chain operations, enabling businesses to achieve greater efficiency, accuracy, and environmental sustainability.Driving Innovation for Environmental, Economic, and Social SynergyAI Analytics Order Demand Forecasting Application is an intelligent solution that embodies the principles of “Big Data, Small Model, Multiple Scenarios, Intelligent Application” within its Model-as-a-Service (MaaS) framework. By integrating large dataset model and self-developed intelligent algorithm through deep learning, the solution builds a comprehensive knowledge base for business applications.  Leveraging computing resources deployment and cross-dimensional training cycles, AI Analytics Order Demand Forecasting Application delivers a “ready-to-use” solution that enable enterprises to utilize advanced algorithms development platform right away, without the need for extensive model training.  This solution efficiently provides intelligent and visualized key data analysis, enabling enterprises to stay informed about the latest business dynamics and operational scenarios. It drives significant value by enhancing supply chain efficiency, reducing waste, and promoting sustainable practices. Serving as the core engine of supply chain operations, AI Analytics Order Demand Forecasting Application seamlessly connects material procurement and production activities. By leveraging cutting-edge AI technologies, including deep learning and large language models (LLMs), it enables precise demand forecasting, further reducing material waste, optimizing resource use, and minimizing environmental impact. Economically, it lowers operational costs, improves cash flow, and enhances efficiency through real-time data analysis. Socially, it empowers enterprises to respond swiftly to market demands, ensuring timely deliveries and higher customer satisfaction. AI Analytics Order Demand Forecasting Application demonstrates the practicality in real business situations and exemplifies how innovation can drive sustainability, economic growth, and social progress simultaneously.Mr. Ivan Lee, Vice President of Innovative Research & Development and Information Technology of CITIC Telecom CPC, said, “We are deeply honored to receive this prestigious award, which underscores our commitment to driving innovation in sustainable technology. AI Analytics Order Demand Forecasting Application represents a transformative approach to supply chain management, combining advanced AI with practical, scalable solutions that empower businesses to thrive in a rapidly changing world. By reducing waste, enhancing supply chain sustainability, improving customer satisfaction, and driving economic efficiency, we are proud to contribute to a greener, more socially responsible, and economically sustainable future.”  CITIC Telecom CPC is advancing sustainability by integrating innovative technology with green practices, driving efficiency across industries. Committed to achieving ESG goals, CITIC Telecom CPC cultivates a robust network of ecosystem partners, delivering AI-driven solutions that empower enterprises to enhance efficiency, reduce costs, and achieve their sustainability visions.About Hong Kong Sustainable Development Innovation and Technology AwardsHong Kong Sustainable Development Innovation and Technology Awards is organized by the World Institute of Sustainable Development Planners, supported by the Innovation and Technology Commission, various government departments and agencies, as well as research, academic and industry sectors. These awards aim to recognize and reward institutions, enterprises, and technology talents across various industries for integrating sustainability principles into their innovative technology, from development, planning, application, to solutions. Allowing all sectors of society to understand Hong Kong’s accomplishments and contributions in sustainable I&T development.For more information, please visit https://wisdp.org/wp/hksdit2025/.About CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI). Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across more than 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SDWAN gateways, 20 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises. We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.For more information, please visit www.citictel-cpc.com.Media Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536 Email: catherine.yuen@citictel-cpc.com Copyright 2025 ACN Newswire via SeaPRwire.com.

DX Leaders Philippines 2025: Accelerating IT Innovation in a $40B Digital Economy

MANILA, Mar 10, 2025 - (ACN Newswire via SeaPRwire.com) - As the Philippines moves toward an estimated $40 billion digital economy by 2025, digital transformation has become a strategic priority for businesses nationwide. DX Leaders Philippines 2025 will bring together 100+ CIOs and IT leaders at Fairmont Makati, providing a collaborative platform to explore next-gen technologies—from AI and cloud computing to cybersecurity and IoT—and how they can drive real business impact in today’s digital-first world.With 60% of global business and IT leaders identifying digital transformation as a key growth driver by 2026(PwC), this forum will explore how enterprises can harness these advancements to enhance efficiency, optimize productivity, and tackle operational challenges.Adding to the momentum, Boomi and Nexus Technologies, Workato as Gold Sponsors, Teleperformance as Plenary Sponsor, Freshworks and Corqspace as Silver Sponsors, and Kissflow as an Associate Partner will play a pivotal role in this year’s event. Meanwhile, Sotnet and RPA Python will spearhead networking initiatives, ensuring high-value conversations and connections among industry leaders.Bridging the Digital Divide: Overcoming Barriers to InnovationWhile the Philippines is rapidly advancing in digital transformation, challenges remain in achieving a fully tech-enabled future. DX Leaders Philippines 2025 is set to tackle these obstacles under the theme: "Staying Digitally Fit with Next-Gen Tech to Accelerate IT Innovation Surge."This forum will equip CIOs and IT decision-makers with cutting-edge strategies, industry best practices, and actionable insights to drive sustainable digital growth. Through expert-led keynotes, dynamic panel discussions, fireside chats, and interactive roundtables, attendees will gain the knowledge needed to future-proof their organizations and maximize the potential of emerging technologies.A Big Comeback: EDX Expands RoadshowX to Conquer the Digital WorldAlecs Andrade, Director of Marketing and Operations at EDX, shares his excitement about this year’s expanded roadshow:“We’re thrilled to bring DX Leaders back to the Philippines as part of our RoadshowX series. This year marks a major comeback, and what makes it even more exciting is that we’re not stopping here—we’re also heading to Malaysia and Indonesia once again. The level of innovation and collaboration we’re seeing in these markets is incredible. Our goal is to deliver a high-impact experience, where IT leaders gain invaluable industry insights and build meaningful partnerships that propel their digital transformation journey forward.”Stay Tuned – EDX’s RoadshowX is Set to Conquer the Digital World!With industry pioneers, innovators, and decision-makers coming together, DX Leaders Philippines 2025 at Fairmont Makati promises to be a game-changing event for enterprises looking to thrive in the digital economy.Stay tuned as EDX’s RoadshowX sets out to conquer the digital world—one transformative event at a time!About EDXAt EDX Pte. Ltd., we are committed to building alliances that support leaders and companies in addressing the pressing challenges of digital transformation, cybersecurity, and customer experience.Whether through our EDXchange sessions, dynamic forums, one-on-one matched meetings, or custom events catered to your needs, we build engaging platforms meant to accelerate executive learning and collaboration. We enable decision-makers to exchange insights and open up new avenues for growth and innovation by fostering these deep connections.Our mission is to establish a cooperative environment where business executives from many sectors can interact, exchange knowledge, and work together to manage the challenges of the modern digital world enabling them to remain competitive in a constantly shifting environment.Website: https://edxevents.com/For more information, please contact:Alecs AndradeEDX Eventsalecs@edxevents.com  Copyright 2025 ACN Newswire via SeaPRwire.com.

雲頂新耀「AI+創新藥」第一股成港股18A黑馬

香港, 2025年3月10日 - (亞太商訊 via SeaPRwire.com) - 近年來,AI賦能創新藥研發已成為全球生物醫藥行業的重要趨勢,尤其在mRNA疫苗領域,AI更是成為提升研發效率與精准度的核心驅動力。港股創新藥企雲頂新耀(HKEX 01952.HK)已實現異軍突起,憑藉多項專有技術率先實現從「18A創新藥」公司到具備專有技術的「AI科技+創新製藥」公司的跨越。近日,雲頂新耀宣佈自主研發的新型mRNA個性化腫瘤治療性疫苗EVM16完成首例患者給藥,成功進入臨床階段,並向外界展示了其在「AI+mRNA」 技術創新、腫瘤治療性疫苗等mRNA腫瘤治療性產品等研發等維度的規劃和進展,包括腫瘤相關抗原(TAA)疫苗EVM14已於今年2月遞交美國FDA IND申請,並會在近期向中國國家藥品監督管理局藥品審評中心遞交IND,引起資本市場的關注。當日該公司股價順勢漲至超過60港元,創下近三年半新高,並成功突破2020年IPO發行價,被業內稱為「AI+創新藥」第一股。在業內看來,雲頂新耀之所以引領港股的強勢反彈,其作為國內首個將由AI驅動的mRNA腫瘤治療性疫苗進入臨床階段的生物製藥公司,擁有自主研發的「妙算」mRNA序列算法系統,並領先佈局千億mRNA腫瘤疫苗賽道,實現了從「18A創新藥」公司到「AI科技」公司的跨越,帶動公司價值重估。專有的「妙算」mRNA序列算法系統已迭代至第三代近年來,AI技術全方位滲透到創新藥開發的各個環節,從基礎研究到臨床試驗,從靶點發現到藥物分子設計,帶來了前所未有的突破。美國在1月份宣佈啟動五千億美元的AI基礎設施建設計劃「星際之門」,出資方包括OpenAI、甲骨文、軟銀等,而其中一項核心應用就是挖掘「AI +創新藥」在癌症治療領域潛力。OpenAI創始人薩姆・奧爾特曼認為AI對創新藥研發可發揮關鍵作用;諾貝爾獎得主、DeepMind CEO丹米斯·哈薩比斯表示,用AI治癒所有疾病不再遙遠。2023年諾貝爾生理學或醫學獎授予mRNA疫苗技術奠基人Katalin Karikó與Drew Weissman,目前mRNA技術應用已從傳染病防治領域延伸至腫瘤治療領域。而在mRNA腫瘤疫苗領域,AI更是成為提升研發效率與精准度的核心驅動力。甲骨文創始人拉裡·埃裡森宣佈了一項AI驅動的腫瘤疫苗系統計劃,並表示通過AI技術在約48小時內可以自動生產出這類mRNA。除美國外,多國均積極支持AI驅動的mRNA腫瘤治療產品研發,例如英國向BioNTech發放1.29億英鎊補貼,韓國強調於2028確保獲得mRNA腫瘤疫苗領先地位。作為全球AI驅動mRNA技術的先行者,雲頂新耀近四年來依託AI驅動的端到端mRNA研發平台,實現了從靶點篩選、序列設計到遞送優化的效率躍升,推動了mRNA腫瘤疫苗治療領域的變革。目前,雲頂新耀專有的「妙算」mRNA序列設計算法系統經過四年多的技術升級已經迭代到第三代。第一代算法目標是優化密碼子使用,實現序列合成及生產風險最小化;第二代算法實現了密碼子和RNA二級結構共同優化;第三代實現UTR(非編碼區)和CDS(編碼序列)共同優化的AI評分模型。通過第三代AI技術賦能算法模型,能夠把第一代算法得到的蛋白表達大概提升5倍左右。並且,該算法通過大數據模型還在持續迭代中。此外,雲頂新耀開發了基於新型可電離脂質的專有LNP遞送系統,可通過被動和/或主動靶向實現組織和細胞特異性遞送。其擁有的陽離子脂質庫能夠產出比SM102等更高免疫原性的脂質,而免疫原性的提高使得小鼠腫瘤模型中的療效更顯著。同時,該可電離脂質在血液、肝臟器官中能比SM102得到更快清除,從而降低了可能引發的毒性反應,效率更高的同時安全性也更好。雲頂新耀還擁有經過臨床驗證的mRNA技術平台。在此前新冠疫苗的開發中,雲頂新耀的mRNA序列優化技術能夠精准設計編碼新冠病毒關鍵抗原的 mRNA 分子,遞送進入人體後,能夠高效且穩定地表達抗原,刺激免疫系統產生強烈的免疫反應,其在海外開展的II期臨床試驗中表現出與BioNTech疫苗相當的免疫原性,而在安全性方面則表現出更好的趨勢。此次公佈里程碑進展的EVM16,是雲頂新耀自研、由AI算法驅動識別腫瘤新抗原的mRNA個性化腫瘤治療性疫苗,其核心優勢在於雲頂新耀基於深度學習的自研「妙算」系統(EVER-NEO-1)新抗原預測算法來篩選新抗原。相比於全球領先的癌症治療與研究機構紀念斯隆凱特琳癌症中心(MSKCC)開發的新抗原識別AI「妙算」算法系統(EVER-NEO-1)在腫瘤新抗原預測方面,在所有三個排名區間(前20、前30、前34)中均展現出更高的捕獲能力,展現出顯著的競爭優勢。「妙算」系統(EVER-NEO-1)新抗原預測算法在人體新抗原免疫原性數據上得到驗證,已發表的mRNA個性化腫瘤疫苗I期研究免疫原性數據顯示,在EVER-NEO-1算法賦能下,新抗原總計檢測率高達79.3%。經過了腫瘤新抗原大數據不斷訓練過的「妙算」系統(EVER-NEO-1)新抗原預測算法,其設計的個性化腫瘤治療性疫苗顯示出優異的免疫原性和安全性,在正常小鼠中激發強烈的免疫原性,在同源腫瘤模型中顯示出更好的有效性,並進行了非人靈長類實驗,在恒河猴體內產生強力且持有的T細胞應答,業界認為其已具備較強的全球競爭力和商業化潛力。開拓腫瘤治療性疫苗千億新藍海值得一提的是,個性化腫瘤治療性疫苗不但療效突出,還可顯著降低多種癌症的復發風險,增強免疫治療的臨床應答,這在此前BioNTech和Moderna的研究中得到證實。BioNTech的個性化腫瘤疫苗在「癌症之王」胰腺癌臨床試驗中表現優異,75%的免疫應答者在3.2年隨訪期內未出現復發,復發風險降低86%;Moderna的疫苗與K藥聯用,與K藥單用相比,復發或死亡風險減少49%。數據顯示,全球mRNA治療市場正快速擴張,規模預計從2024年的196.8億美元躍升至2034年的426.4億美元。而雲頂新耀憑藉AI驅動的自主知識產權的mRNA技術平台,多路徑佈局腫瘤及其他治療性mRNA藥物研發,且擁有相關產品的全部知識產權及全球權益。除EVM16外,公司多個mRNA腫瘤治療藥物包括腫瘤相關抗原(TAA)腫瘤治療性疫苗、免疫調節腫瘤治療性疫苗,以及自體生成CAR-T產品也在研發過程中,並著力開發新一代 LNP 遞送系統,增強細胞介導的免疫反應,全方位提升公司在mRNA藥物研發領域的競爭力。其中,EVM14的一大突破在於可誘導免疫記憶,防止腫瘤復發。此外自體生成CAR-T項目已經完成了一項非人類靈長類動物(NHP)研究,繼續向臨床前候選分子選擇階段推進。相比于傳統自體CAR-T療法,mRNA自體生成CAR-T擁有無需淋巴耗竭化療、可大規模生產等有點,有望解決傳統CAR-T療法面臨的生產成本高等挑戰。雲頂新耀首席執行官羅永慶表示,AI正重塑生物醫藥研發格局,尤其在mRNA疫苗領域。EVM16首例患者的成功給藥,標誌著雲頂新耀自主知識產權的腫瘤新抗原AI算法系統和mRNA 技術平台成功邁入人體試驗階段。「目前,公司已成功將自研且經過臨床驗證的mRNA平台本地化,構建起從抗原設計、mRNA 序列優化、LNP 遞送技術到產業化生產的端對端全產業鏈平台,具備在全球範圍滿足巨大未滿足醫療需求的潛力。」成立七年以來,雲頂新耀成功引進了耐賦康®、依嘉®、伊曲莫德等多款在亞洲人群有巨大臨床需求的重磅產品。經過過去三年多的戰略轉型,雲頂新耀已從授權引進模式為主,成功轉型為自主研發和授權引進並行的「雙輪驅動」模式。當前,從科學界、產業界到各國政府,mRNA技術已被定位為腫瘤治療領域的戰略級技術。雲頂新耀通過「AI+mRNA」技術協同佈局,不僅夯實強化了其在創新藥領域的先發優勢,更可能憑藉這一技術組合成為BD合作的關鍵支點,在全球創新藥競爭格局中佔據更有利的戰略位置。「AI技術在腫瘤診療領域的應用價值已形成全球共識,而如何以AI賦能mRNA技術平台加速新藥研發,更是全球範圍的重大趨勢,雲頂新耀將在這一進程中積極嘗試和不斷突破。」羅永慶表示。 Copyright 2025 亞太商訊 via SeaPRwire.com.

APEL產品揚威國際:重新定義健康與可持續發展 – 邁向變革性發展

APEL在大阪Knowledge Capital舉行的互動展覽現已開幕,並將持續至2025年12月底。香港, 2025年3月10日 - (亞太商訊 via SeaPRwire.com) - 隨著2025年日本大阪關西世界博覽會(以下簡稱「世博會」)即將揭開序幕,義合控股有限公司(香港主板上市編號: 1662)之間接非全資附屬公司Absolute Pure EnviroSci Limited(以下簡稱「APEL」或「本公司」)正式發佈其雄心勃勃的計劃,旨在重新定義日本健康與可持續發展。APEL的舉措與大阪世博會的主題「構建未來社會,想像明日生活」深度契合,彰顯其對解決人類與生態福祉相關的全球迫切挑戰的堅定承諾。APEL願景:以科學和可持續發展革新醫療保健、環境及寵物健康領域APEL的核心使命是通過創新來解決全球挑戰。基於本公司的使命,APEL的策略性路線圖致力於將解決方案應用於醫療保健、環境及寵物健康領域。APEL在大阪Knowledge Capital舉行的互動展覽現已開幕,並將持續至2025年12月底。此次展覽與世博會相輔相成,將作為一個互動平台,吸引來自世界各地的訪客,展示領先科技、凝聚利益相關者並建立加速正面影響力的聯盟。義合控股有限公司(香港主板上市編號: 1662)主席詹燕群先生(右三)、APEL董事楊學光博士(右二)及APEL主席鍾偉强博士(右一)與研討會嘉賓合照。APEL於大阪舉行生物醫藥技術創新專家研討會。APEL革命性產品陣容彰顯其策略雄心APEL三大旗艦創新-WisepuraTM、GERMAGICTM及GERMAGICTM PET精準針對日本迫切需求,兼具可擴展性:1. WisepuraTM:重塑公共衛生標準與香港科技大學聯合研發的WisepuraTM致力於對抗抗菌素耐藥性與環境危害:- WisepuraTM Aquapura:一種長效抗菌材料,用於消除異味和保障水質安全。  - 目標:在2025年10月前將此技術應用於100+個公共設施,減少高達 99%的水媒病原體。- WisepuraTM Airpura:一種抗菌塗層,用於空氣淨化。  - 目標:攜手15+個日本智慧城市,減少交通系統中的空氣傳播感染。2. GERMAGICTM:在各種環境提高衛生標準基於獲全球20+間機構認證的多層次殺菌塗層技術(MAP-1),GERMAGICTM將革新5,000億日圓規模的日本衛生市場:- 飛機空氣淨化:與日本領先航空公司合作,計劃在2025年第四季前將MAP-1應用於200+架飛機,減低高達60%的機艙病菌傳播。- 智能建築整合:與Techno Frontier合作,將MAP-1融入環保建材,目標實現暖通空調系統節能30%。3. GERMAGICTM PET:提升人寵共生關係APEL以科技驅動的寵物護理品牌融合了診斷與抗菌解決方案:- 目標:在2026年前佔據1.2兆日圓的日本寵物市場的10%份額,在都市家庭減少高達50%與寵物相關的過敏。- 創新:於東京和大阪設立寵物健康中心,為50,000+隻寵物提供即時健康監測。  APEL三大旗艦創新-WisepuraTM、GERMAGICTM及GERMAGICTM PET。建立堅定信心:日本各界領袖全力支持APEL2025年3月6日,APEL於大阪舉辦了一場專家研討會,標誌著APEL重要的里程碑,並匯聚了日本企業、學術界和政府代表,包括:Knowledge Capital總製作人野村卓也先生 (Takuya Nomura) 、香港貿易發展局大阪事務所長Ricky Fong先生、日本經濟同友會幹事古川令治先生 (Ryoji Furukawa) 、京都大學前川真治教授 (Shinji Maegawa) 、 Quantum Life創始人兼首席執行官黃園醫學博士、Techno Frontier社長河原利和先生(Kawahara Toshikazu)、創域互動有限公司創始人張偉文先生及GERMAGIC™上海總經理鍾耀武先生。邁向變革性健康與環境保護發展APEL主席鍾偉强博士表示:「在我們不懈應對全球挑戰的過程中,我們致力將科學研究轉化為提升生活品質及居住環境的實效應用。我們深感榮幸在本次研討會獲得日本各界鼎力支持。同時,本次研討會標誌著APEL在全球拓展健康與環境科技創新的新篇章。在進軍日本市場之際,我們期待與當地研究人員、機構及企業合作,開發領先解決方案以應對全球迫切挑戰,共創更美好的明天。」在大型展覽會和專家研討會的推動下,APEL深信其創新成果將帶來顯著效益,提升健康與福祉,並促進可持續發展。各界對這些發展的殷切期待,體現了APEL追求卓越的承諾和建立更健康世界的願景。  關於APELAbsolute Pure EnviroSci Limited(「APEL」)為香港聯合交易所主板上市公司-義合控股有限公司(香港主板上市編號: 1662)的間接非全資附屬公司,以改善生活品質及居住環境為使命,主要從事健康與環境科技創新的研究、開發及商業化。基於其多層次殺菌塗層技術(MAP-1),APEL已在四個關鍵領域:飛機空氣淨化、水質淨化、畜牧健康和環保建材,研發專門的應用配方,旨在應對全球迫切挑戰。APEL期待與全球研究人員和行業夥伴合作,推動更多健康與環境科技創新。傳媒如有查詢,請聯絡:庾婉華羅思正電話:+852 9500 4443電話:+852 9326 1113電郵:avy.yu@ajacapital.com.hk電郵:eudice.law@ajacapital.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

中信國際電訊CPC榮獲2025香港可持續發展創新科技大獎

香港, 2025年3月10日 - (亞太商訊 via SeaPRwire.com) - 中信國際電訊集團有限公司(「中信國際電訊」,香港交易所股份代號:1883)全資擁有的中信國際電訊(信息技術)有限公司(「中信國際電訊CPC」)欣然宣布榮獲2025香港可持續發展創新科技大獎的「綠色供應鏈創新科技」卓越獎。中信國際電訊CPC憑藉創新解決方案「智化算 (AI Analytics)」,為可持續供應鏈管理帶來的突破及卓越價值而榮獲殊榮。中信國際電訊CPC榮獲2025香港可持續發展創新科技大獎【綠色供應鏈創新科技】卓越獎香港可持續發展創新科技大獎旨在嘉獎各行各業的機構以及創科人才,以表彰其因應自身行業和業務範圍,將可持續發展理念融入創新科技。中信國際電訊CPC的「智化算」憑藉其將人工智能(AI)和機器學習技術融入供應鏈營運的能力脫穎而出,賦能企業實現更高的效率、準確性和環境可持續性。以創新驅動環境、經濟與社會共贏「智化算」訂單需求智能預測解決方案是基於「大數據、小模型、多場景、智能應用」的理念,並採用「模型即服務」(MaaS)框架開發。方案透過深度學習結合大語言模型,融合自主研發並獲多項專利的智能演算法,構建訂單需求預測多模態知識庫。通過算力資源調配及跨維度循環訓練,糅合創新技術將人工智能大模型變成針對客戶生產模式的數據分析應用方案,讓企業不再受限於零樣本、小樣本場景,打造一個真正的"拎包入住"的算法應用方案。快速為企業提供智能化及可視化關鍵數據分析,賦能企業掌控最新業務動態及營運格局提升供應鏈效率、減少浪費以及推動可持續實踐,創造顯著價值。「智化算」訂單需求預測解決方案是貫通物料採購和生產活動中的"中樞神經",確保流程高效運作。通過利用嶄新AI技術,包括深度學習和大語言模型(LLMs),「智化算」實現了精準的需求預測,進一步減少材料浪費、優化資源使用並最小化環境影響。在經濟層面,方案有效降低了營運成本、改善了現金流,並通過實時數據分析提升效率。在社會層面,方案讓企業能夠快速回應市場需求,確保及時交付並提高客戶滿意度。「智化算」訂單需求預測解決方案展示了在實際商業場景中的實用性,並彰顯了創新如何同時推動可持續發展、經濟增長和社會進步。中信國際電訊CPC創新研發及信息技術部副總裁李超群先生表示:「我們深感榮幸獲得此殊榮,彰顯了我們在推動可持續技術創新方面的承諾。「智化算」訂單需求預測解決方案代表了一種突破性的供應鏈管理方法,將人工智能(AI)與實用及可擴展的解決方案無縫結合,賦能企業在快速變化的環境中穩步前行。通過減少浪費、提升供應鏈可持續性、提高客戶滿意度並推動經濟效率,我們為實現更綠色、更具社會責任感和經濟可持續的未來感到自豪。」中信國際電訊CPC以創新科技賦能綠色實踐,推動可持續發展,重塑行業效率新高度。聚焦ESG目標,中信國際電訊CPC構建強大生態伙伴圈,通過AI創新解決方案,賦能企業高效轉型,降本增效,引領可持續發展新未來。關於香港可持續發展創新科技大獎香港可持續發展創新科技大獎由全球可持續發展規劃師學會主辦,創新科技署及多個政府部門與産學研單位全力支持。旨在透過嘉獎各行業的機構、企業以及創科人才,以表彰其因應自身行業和業務範圍,將可持續發展理念融入創新科技,從開發、規劃、應用、發展及解決方案均以可持續發展為原則,並讓社會各階層能夠接觸和了解香港在可持續創科發展的成就和貢獻。詳情參閱https://wisdp.org/wp/hk/hksdit2025/。中信國際電訊CPC簡介中信國際電訊(信息技術)有限公司(「中信國際電訊CPC」)是中信國際電訊集團有限公司(香港交易所股份代號:1883)的全資附屬公司,一直矢志透過先進技術及旗艦解決方案,包括TrueCONNECT™專用網絡服務、TrustCSI™信息安全解決方案、DataHOUSE™全球統一雲數據中心解決方案及SmartCLOUD™雲端運算解決方案,為全球跨國企業提供綜合數碼解決方案,滿足不同行業的ICT服務需求。憑借「創新‧不斷」的服務理念,中信國際電訊CPC積極利用創新技術,提煉"技術賦能",將人工智能、擴增實境、大數據,物聯網和其他尖端新興技術,融合深度學習及智能數據分析技術,轉化為"數據賦能"生成式AI+應用,重塑企業智能營運之旅。中信國際電訊CPC以「服務在地,連接全球」的優勢,承諾為客戶提供最優質的一站式ICT服務。全球化網絡資源連接近170個服務據點、60多個SDWAN 網關;20個雲服務中心、30多個數據中心及3個全天候運作的安全運作中心,服務遍布逾160個國家和地區,無縫連接亞洲、歐美、非洲、中東以及中亞等地區。透過全球化服務佈局,多年不斷深耕各個行業與領域經驗,一系列國際認證(SD-WAN Ready, ISO 9001、14001、20000、27001 及27017),確保為企業提供國際化標準及專業在地服務能力,成為客戶信賴的信息智能化服務供應商。請瀏覽www.citictel-cpc.com獲取更多資訊。傳媒查詢:Catherine Yuen中信國際電訊CPC(852) 2170 7536 電郵:catherine.yuen@citictel-cpc.com Copyright 2025 亞太商訊 via SeaPRwire.com.

The PropertyGuru Asia Awards Malaysia in Partnership with iProperty return with 23 new categories in 2025

THE 12TH EDITION OF MALAYSIA’S PREMIER REAL ESTATE AWARDS PROGRAMME EXPANDS WITH ADDITIONAL ACCOLADES FOR ACHIEVEMENTS IN DEVELOPMENT AND DESIGN NATIONWIDEThe independent panel of judges gather in Kuala Lumpur on 26 February for the launch of the 2025 edition of the PropertyGuru Asia Awards Malaysia in partnership with iPropertyKUALA LUMPUR, Mar 10, 2025 - (ACN Newswire via SeaPRwire.com) - The PropertyGuru Asia Awards Malaysia in partnership with iProperty return for their 12th edition in 2025 with more categories than ever before.Part of the PropertyGuru Asia Property Awards series, which marks its historic 20th edition in 2025, the enhanced awards programme will recognise excellence in property development and design throughout Malaysia. Supported by the country’s leading property portals, PropertyGuru.com.my and iProperty.com.my, the awards are expected to set new benchmarks for the property sector nationwide.Key dates for the 2025 edition are as follows:30 May 2025 – Entries Close17-29 June 2025 – People’s Choice Awards Voting Period1-3 July 2025 – Live Judging Days9 October 2025 – Gala Dinner and Awards Ceremony in Kuala Lumpur, Malaysia12 December 2025 – Regional Grand Final Gala Dinner and Awards Presentation in Bangkok, Thailand  Expanding award categoriesWith the continued expansion of the real estate market, the PropertyGuru Asia Awards Malaysia in partnership with iProperty are launching a total of 132 categories in 2025. These categories were officially unveiled during launch events in Johor Bahru on 24 February 2025 and in Kuala Lumpur on 26 February 2025, attended by industry stakeholders ranging from company representatives to judges and customers.This year’s edition of the PropertyGuru Asia Awards Malaysia in partnership with iProperty also launched from Johor Bahru on 24 FebruaryThis year’s edition introduces nine new awards recognising outstanding landed and high-rise developments in the Central, Northern, and Southern regions of Malaysia. These are Best Ultra Luxury Landed Development (Central); Best Ultra Luxury Landed Development (Northern); Best Ultra Luxury Landed Development (Southern); Best Mid End Landed Development (Central); Best Mid End Landed Development (Northern); Best Mid End Landed Development (Southern); Best Ultra Luxury High-Rise Development (Central); Best Ultra Luxury High-Rise Development (Northern); and Best Ultra Luxury High-Rise Development (Southern).Seven new categories will honour residential projects across all regions of Malaysia: Best Townhouse Development; Best Completed Mixed Use Development; Best Oceanview High-Rise Development; Best Oceanview Landed Development; Best Serviced Apartment Development; and Best Heritage Development.Two new categories will recognise outstanding commercial projects throughout the country: Best Lifestyle Commercial Development and Best Nature Integrated Development.Finally, six design categories have been introduced to celebrate excellence in architecture and interior aesthetics: Best Townhouse Architectural Design; Best Townhouse Interior Design; Best Sales Gallery Design; Best Retail Interior Design; Best Office Architectural Design; and Best Townhouse Landscape Design.The expansion of categories builds on the success of the ESG Developer Awards introduced at the 2024 awards, reinforcing PropertyGuru’s support for sustainable development. These special awards will return this year and recognise five champions in ESG initiatives.Ongoing, meaningful changeDatuk Ar. Ezumi Harzani Ismail, president of the Malaysian Institute of Architects (PAM) 2020-2022 and chairperson of the judging panel, said: “The quality of last year’s award winners reflected ongoing, meaningful change within Malaysia's property sector and highlights our market’s ability to adapt and elevate standards. Participating in the awards is essential for developers as it not only establishes higher benchmarks in real estate development and design but also promotes healthy competition as well as collaborative innovation. Ultimately, our industry benefits by guiding consumers toward affordable and aspirational built spaces."Led by Datuk Ar. Ezumi Harzani Ismail, a 14-member panel of specialists will assess entries and select winners during the Live Judging Days In July 2025. The panel of judges comprise diverse experts including town planners, ESG consultants, valuers, engineers, property managers, architects, designers, and legal experts.Various developers and customers join the launch of the awards in Kuala LumpurAs the official supervisor of the awards, HLB Ler Lum Chew – HLB Malaysia, part of “2024 Network of the Year” winner HLB International, will oversee this selection process, ensuring the credibility of the judging system.Meanwhile, the People’s Choice Awards will empower the public to vote in June 2025 for their favourite developers based on reputation, track record, timely project delivery, and overall quality. As official balloting partner, HLB Ler Lum Chew – HLB Malaysia will verify the results of this public voting process.All winners will be revealed during a prestigious gala dinner and awards ceremony at the St. Regis Kuala Lumpur in October 2025.Representing Malaysia on the international stageMajor winners of the 12th PropertyGuru Asia Awards Malaysia in partnership with iProperty will represent the country on the international stage at the 20th PropertyGuru Asia Property Awards Grand Final in December 2025. Leading developers from across Asia Pacific, including those from markets such as the Middle East, Mainland China, Hong Kong, Macau, Japan, Australia, India, Sri Lanka, Cambodia, Indonesia, the Philippines, Singapore, Thailand, and Vietnam, will compete against those from Malaysia at the 2025 Grand Final.At last year’s Grand Final, Malaysian projects earned various awards, with winners including Bangsar Heights Pavilion, Berinda Group, City Motors Group, Eupe Corporation Berhad, Gunung Impian Development Sdn Bhd, Iskandar Investment Berhad, JLand Group Sdn Bhd, Malton Berhad, Sime Darby Property Berhad, Tropicana Corporation Berhad, and Triterra Sdn Bhd.Organised by PropertyGuru Group, the 12th Annual PropertyGuru Asia Awards Malaysia in partnership with iProperty are supported by official portal partners PropertyGuru.com.my and iProperty.com.my; official ESG knowledge partners Green Building Index, GreenRE and Malaysia Green Building Council; official magazine Property Report by PropertyGuru; and official supervisor and balloting partner HLB.For more information, email awards@propertyguru.com or visit the official website: AsiaPropertyAwards.com/en/award/malaysia.ABOUT PROPERTYGURU ASIA PROPERTY AWARDSPropertyGuru’s Asia Property Awards, established in 2005, are the region’s most exclusive and prestigious real estate awards programme. The Asia Property Awards are recognised as the ultimate hallmark of excellence in the Asian property sector. Boasting an independent panel of industry experts and trusted supervisors, the Awards have an unparalleled reputation for being credible, ethical, fair, and transparent. In 2025, the Awards series is open to key property markets around the region. The exciting gala events welcome senior industry leaders and top media, as well as reach property agents and consumers via live streaming. Recognising excellence within each Asian market with a variety of categories, including green and sustainable development, each local awards programme will culminate in the PropertyGuru Asia Property Awards Grand Final, which takes place after the PropertyGuru Asia Real Estate Summit during PropertyGuru Week in December 2025. For more information, please visit AsiaPropertyAwards.com.ABOUT PROPERTYGURU GROUPPropertyGuru is Southeast Asia’s leading(1) PropTech company, and the preferred destination for over 31 million property seekers(2) to connect with over 50,000 agents monthly(3) to find their dream home. PropertyGuru empowers property seekers with more than 2.1 million real estate listings(4), in-depth insights, and solutions that enable them to make confident property decisions across Singapore, Malaysia, Thailand, and Vietnam.PropertyGuru.com.sg was launched in Singapore in 2007 and since then, PropertyGuru Group has made the property journey a transparent one for property seekers in Southeast Asia. In the last 17 years, PropertyGuru has grown into a high-growth PropTech company with a robust portfolio including leading property marketplaces and award-winning mobile apps across its core markets.  For more information, please visit: PropertyGuruGroup.com; PropertyGuru Group on LinkedIn.(1) Based on SimilarWeb data between January 2024 and June 2024.(2) Based on Google Analytics data between January 2024 and June 2024.(3) Based on data between April 2024 and June 2024.(4) Based on data between January 2024 and June 2024.PROPERTYGURU CONTACTS:General Enquiries:Richard Allan Aquino, Head of Brand & Marketing ServicesM: +66 92 954 4154E: allan@propertyguru.com   Media & Partnerships:Piyachanok Raungpaka, Senior Media & Marketing Services ExecutiveM: +66 94 887 5163E: piyachanok@propertyguru.comSales & Nominations:June Fong, Director of Awards and Events (Malaysia)M: +6012-6594394E: june.fong@iproperty.com.my  Copyright 2025 ACN Newswire via SeaPRwire.com.

World’s Most Sleep-Deprived Nation Has a Gender Crisis: Why Singaporean Women Bear the Heaviest Burden

SINGAPORE, Mar 10, 2025 - (ACN Newswire via SeaPRwire.com) - Living in a highly-productive and high-performance society like Singapore does have its benefits - breeding a highly-competitive environment where efficiency is achieved, stability is maintained, and getting full value is often the name of the game. In Singapore, its citizens have accepted this as the status quo.However, Singapore has also been found to be the most exhausted and sleep-deprived nation in the world, scoring 7.2 out of 10 on a fatigue scale, with only 44% of the population getting the recommended seven hours of sleep. As we mark International Women’s Day and World Sleep Day this March, research has shown that this hidden crisis of sleep deprivation disproportionately impacts women. The numbers expose a brutal truth:Women are twice as likely to have insomnia (Michigan Medicine)33% of women wake up every night (Sleep Foundation)37% of women report losing sleep due to hormone-related conditions (Sleep Foundation)Beyond increasing the risk of heart disease, diabetes, and depression, sleep deprivation launches a direct assault on women’s health and appearance. During sleep, the body’s natural repair mechanisms regenerate skin cells, produce collagen, and fight premature aging. When sleep is compromised, the consequences are profound:Accelerated skin agingIncreased inflammationReduced skin cell turnoverDull, tired complexionLAC understands that addressing sleep is more than a wellness strategy - it’s a form of empowerment. Their comprehensive range tackles both internal sleep challenges and external skin restoration, supporting women’s holistic health.LAC addresses this gap with its TriAction Sleep Formula, a supplement designed to support the natural sleep cycle through a unique triple-layer technology. The formula is engineered to release key sleep-supporting nutrients at different stages:Pre-Sleep Phase: While still awake, the first layer works to calm the mind and body using a blend of Valerian Root Extract, Saffron Extract, Magnesium, and Melatonin, signaling that it’s time to unwind and sleep.Transition to Sleep: After settling into bed, the second layer—with ingredients like L-Theanine and GABA—helps ease the transition into sleep, promoting a faster onset and more stable rest.Sustained Rest: Throughout the night, the third layer gradually releases the same actives, reducing interruptions and helping to maintain a consistent sleep cycle. This controlled release is particularly beneficial for adjusting sleep patterns during travel or shifts in routine.This multi-stage approach aims to help individuals manage common sleep disturbances, ultimately improving mood, reducing daytime fatigue, and supporting the body’s natural repair processes. It is also made with all natural ingredients, preventing over reliance or dependency.Complementing the emphasis on quality sleep is the LAC Taut range, which focuses on protecting against premature skin aging through advanced collagen support.LAC TAUT Rejuvenate+ Premium CollagenThis premium collagen drink delivers a potent 13,000mg of Rapid Delivery System (RDS) low molecular weight fish collagen per serving, sourced from deep-sea red snapper. It's formulated to help restore, firm, and hydrate the skin while combatting Advanced Glycation End Products (AGEs), which are associated with premature aging.LAC TAUT Radiance+ Premium Collagen MaskA high-intensity facial mask infused with hydrolysed collagen, squalane, hyaluronic acid, and antioxidants. In just 7-10 minutes, it aims to enhance skin texture and facial contours, leaving the skin feeling smooth, supple, and lifted.LAC TAUT Miracle Intensive Age-Defying SerumAn ultra-lightweight face serum enriched with premium collagen and antioxidants. This serum is designed to hydrate intensively, repair the skin barrier, and reduce the appearance of fine lines and wrinkles, promoting a more youthful complexion.This March, we invite you to reclaim your rest and restore your vitality: Sleep is not a luxury. It's your most powerful form of self-care. By integrating these products into a regular skincare regimen, alongside prioritising sufficient sleep, individuals can support their skin's natural rejuvenation processes. This combined approach addresses both external care and internal health, reflecting LAC's commitment to comprehensive wellness solutions. Copyright 2025 ACN Newswire via SeaPRwire.com.

uSMART Securities Surges 300% in Hong Kong Local Users

HONG KONG, Mar 10, 2025 - (ACN Newswire via SeaPRwire.com) - uSmart Securities Limited (referred to as "uSMART Securities/ the Company"), strategic investments from Chow Tai Fook Holding , is pleased to announce the opening of two new branches at Lok Ma Chau MTR Station and Hong Kong West Kowloon High Speed Rail Station. Driven by the recent surge in Hong Kong stock market, during the past year, the Company’s local registered user in Hong Kong has increased by 300% compared to the same period last year. To provide a more convenient and high-quality customer experience, uSMART Securities has decided to expand its presence in Kowloon and the New Territories, catering to clients across regions and further broadening its customer base.Recently, China's "Top Ten Technology Stocks" have been performing exceptionally well, rivaling the popularity of the U.S. "Magnificent Seven," and their market valuations remain attractive, drawing significant attention from investors. This investment boom has led to a sharp rise in account opening demand at the Company with expectations of sustained momentum amid favorable market conditions. The Company aims to capitalize on this growth opportunity by simultaneously launching two new branches to strengthen its competitive edge.As the first brokerage to establish branches in MTR stations, this move represents not only an innovative breakthrough but also a significant milestone in the brand's development. To better serve customers, we have strategically chosen these two transportation hubs, which are expected to officially open in mid-2025 and operate seven days a week. Clients can access in-person consultations, account opening services, and investment advisory support, as well as investment planning. If you have any questions while using the uSMART APP, please visit the branch for hands-on assistance.West Kowloon High Speed Rail Station Branch Preliminary RenderingsTo celebrate the upcoming launch of the two new branches, uSMART Securities will introduce a special promotion in April offering 0 commissions and 0 platform fees for trading the “ATM Trio” (Tencent, Alibaba, Meituan) for all account holders. Additionally, the Company welcomes clients to suggest their favorite Hong Kong stocks for promotion offer. Based on these suggestions, we will make adjustments in the third quarter, aiming to deliver even more substantial returns for our clients.To express gratitude for the unwavering support of our valued clients, uSMART Securities is pleased to introduce a series of commission-free offerings, including:1)Invest in 100 Hong Kong Stock ETFs with 0 Commission, 0 Platform Fees* ;2)0 Commission, 0 Platform Fees, and  0 Custody Fees for U.S. and Hong Kong Monthly Investment PlanBoth new and existing clients can enjoy the offers without any hidden clauses. We have designed these promotions to cater to short-term, medium-term, and long-term investment strategies, ensuring that all uSMART Securities clients can benefit.Amid heightened global market activity, during the past year, the number of registered users at uSMART Singapore has surged eightfold year-on-year, demonstrating its robust growth momentum. Simultaneously, uSMART Capital, LLC, a wholly-owned subsidiary of uSMART Group, has officially obtained a brokerage license from the U.S. Financial Industry Regulatory Authority (FINRA), marking a significant milestone in the Group's strategic expansion into global financial markets. Looking ahead, uSMART Securities will continue to leverage technology to drive financial innovation, delivering greater value to clients worldwide.About uSmart Securities LimiteduSmart Securities Limited, a leading tech broker in Hong Kong backed by Chow Tai Fook Holdings, was founded in 2018. Over the past seven years, the Company has pioneered the integration of technology and finance, offering securities, asset management, and wealth management services. To serve global investors, uSMART has exclusively developed the financial trading platforms uSMART HK APP and uSMART SG APP, operated by uSMART Hong Kong and uSMART Singapore, respectively. The Group's APPs support diversified investment and trading services, including Hong Kong stocks, U.S. stocks, A-shares (Stock Connect), Singapore stocks, Japan stocks, U.K. stocks, U.S. options, ETFs, funds, bonds, asset management, structured notes, futures, cryptocurrencies, precious metals, gold, and forex. The Group also offers tailored services for ultra-high-net-worth individuals, families, and enterprises, providing comprehensive and integrated asset management solutions to meet diverse wealth management needs.Learn more: www.usmart.hk/enFor any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

盈立證券激增300%香港本地用戶 開設2家新分行 搶佔市場份額

香港, 2025年3月10日 - (亞太商訊 via SeaPRwire.com) - 由周大福控股戰略入股的uSMART盈立證券有限公司(下稱「盈立證券/ 本公司」)欣然宣佈將在落馬洲港鐵站及西九龍高鐵站開設兩家新分行。受近期港股熾熱投資氣氛帶動,過去1年內,香港本地註册用戶較去年同期增長300%。為提供更便捷及優質的客戶體驗,盈立證券決定在九龍和新界設立新分行,以滿足不同地區客戶的需求,進一步擴大客戶基礎。近期中國『十大科技股』十分火熱,表現媲美美國『神奇七股』,市場估值亦具有吸引力,因此吸引不少投資者的關注。這股投資熱潮使本公司的開戶需求大幅上升,我們預期這勢頭將會持續,並看好未來股市投資環境。因此,盈立證券決定抓緊這個發展機遇,同時開設兩間新分行,提升市場競爭力。 作為首家在港鐵站內設立分行之券商,這不僅是一次創新突破,更是品牌發展中的重要里程碑。為方便客戶,我們特選在這兩個交通熱點開設分行,預計將於 2025 年中隆重開幕,並實施每星期7天營業服務。客戶可在分行面對面與投資顧問進行一般查詢、辦理開戶及諮詢投資理財等事宜。如遇到任何使用流動交易程式時的疑問,客戶亦可亦可親臨分行體驗查詢。西九龍高鐵站分行初步效果圖為慶祝兩家分行即將投入服務,uSMART盈立證券將於4月推出「ATM三巨頭」 (騰訊、阿里巴巴、美團) 免佣 及 免平台費 優惠,惠及所有持有uSMART盈立證券賬戶的客戶。此外,本公司亦歡迎客戶提議心水港股,並將於第三季根據客戶的反饋調整,相信這將為客戶創造更可觀的收益。 為回饋忠實客戶多年的支持,uSMART盈立證券亦同時提供多項 真全免 優惠,包括:1)100隻港股ETF 0佣 0平台費;2)月供美股、港股0佣 0平台費 0存倉費無論新客戶及現有客戶,都可以享受真全免,絕無取巧,我們設計以上優惠,旨在滿足短線、中線及長線投資策略,讓持有uSMART盈立證券賬戶的客戶均能受益。隨著全球股市交投活躍,過去1年內,盈立證券(新加坡)的註册用戶數量較去年同期驟升8倍。最近uSMART盈立集團的全資子公司uSMART Capital,LLC 正式獲批美國 FINRA券商牌照,這標誌著集團在全球金融市場的戰略佈局取得了重大進展。展望未來,uSMART盈立證券將繼續以科技賦能金融,致力於為全球客戶創造更多價值,並推動金融服務的創新與升級。關於uSMART盈立證券:由周大福控股戰略入股的盈立證券是一間領先科技港資券商,成立於2018年,7年來憑藉卓越的戰略規劃和創新能力,致力於將科技與金融深度融合,業務範圍涵蓋證券、資產管理、財富管理等領域,為全球投資者獨家研發了金融證券交易平台 uSMART HK APP和uSMART SG APP,分別由盈立證券(香港)和盈立證券(新加坡)提供服務。集團APP支持港股、美股、A股(滬深港通)、新加坡股票、日本股票、英國股票、美股期權、ETF、基金、債券、資管、結構化票據、期貨、加密貨幣、貴金屬、黃金和外匯等多元化的投資交易服務,此外更為超高淨值個人與家族、企業提供度身訂制服務,打造全方位綜合性資產管理解決方案。 詳情可瀏覽 www.usmart.hk/zh-hk傳媒查詢:黃曉霖 Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

珠寶雙展匯聚逾82,000環球買家

- 香港國際珠寶展於昨天圓滿閉幕,香港國際鑽石、寶石及珍珠展亦於上周四結束- 兩展共吸引來自141個國家及地區、逾82,000名買家親臨採購,展示香港商貿平台的國際影響力- 東盟、中東、西歐和南美買家均見增長- 現場問卷調查結果顯示,買家及展商認為未來兩年珠寶產品於中東市場的增長潛力最大- 逾四成受訪者預計未來一至兩年整體銷售額將會上升,逾五成受訪者預計持平香港, 2025年3月9日 - (亞太商訊 via SeaPRwire.com) - 由香港貿易發展局(香港貿發局)主辦的第41屆香港國際珠寶展以及第11屆香港國際鑽石、寶石及珍珠展,繼續採用「兩展兩地」模式,雲集來自逾40個國家及地區、約4,000家展商參與。珠寶展昨天於香港會議展覽中心圓滿閉幕,而鑽石、寶石及珍珠展已於上周四在亞洲國際博覽館結束。今屆珠寶展首次增設「黃金首飾」展區,蒐羅設計新穎的金飾,以及「新晉珠寶設計師」專區,展示設計新秀的潛力,幫助業界把握新機遇。珠寶雙展共吸引來自141個國家及地區、逾82,000名買家親臨採購,其中有來自125個國家及地區約32,000名買家參與鑽石、寶石及珍珠展,以及來自133個國家及地區約51,000名買家出席珠寶展,東盟、中東、西歐和南美買家均錄得增長,充分彰顯珠寶雙展的國際化。香港貿發局副總裁張淑芬表示:「作為全球領先的珠寶商貿平台,珠寶雙展聯結全球買家,並舉辦超過30場行業講座及活動,推動業界創新及交流,同時積極透過珠寶設計比賽推廣本地設計及發掘業界新秀,展示珠寶雙展於國際珠寶業界的影響力,以及香港作為世界一流會展中心的地位。」展商及買家最看好中東市場為更深入了解珠寶行業趨勢,香港貿發局對現場1,434名參展商和買家進行問卷調查。結果發現買家及展商對經濟前景的態度審慎樂觀,問卷調查重點結果如下:市場及行業展望:44.2%受訪者預計未來一至兩年整體銷售額將會上升,50.6%受訪者預計持平。受訪者認為未來兩年珠寶產品於以下目標銷售市場的增長前景為理想及非常理想:中東(76.8%)、印度(72.6%)、澳洲及太平洋群島(67.8%)、東盟(66.2%)、韓國(66%)。市場潛力方面,最多受訪者正在嘗試開拓的市場分別是歐洲(24.9%)、東盟(15.2%)、北美洲(13.4%)、中東(11.4%)、日本(7.9%)。未來三年,人工智能(62.8%)、大數據(46.9%),以及社交媒體(44.6)的技術進步對珠寶行業影響最大。產品趨勢:受訪者認為今年時尚首飾(61.9%)、貴重珠寶(39.1%)、輕奢首飾(24.4%)有最大增長潛力。黃色K金(43.4%)、白色K金(37.8%)及純黃金(28.6%)是2025年最受歡迎的貴金屬產品。鑽石(47.6%)是今年最受歡迎的寶石,其次是紅寶石(26.2%)、祖母綠(19.1%)。香港貿發局呼應最新公布的政府財政預算案,協助本地企業開拓內地市場及增加電商銷售。今年淘寶天貓首次參與珠寶展,助展商突破地域界限,開拓內地市場,共有10間參展商及六位網紅達人參與,總觸及高達超過600萬人次,銷售額達5,000萬港元。參展商稱銷售額超預期珠寶雙展廣受全球業內人士喜愛,有展商反映銷售喜出望外。在珠寶展,帶來九個設計師的香港展商亞洲珠寶文化設計工藝協會創會會長鄭陳曼芝說:「我們希望透過這次展會接觸中東買家,並開拓新的國際市場,期望銷售額達100萬至300萬美元。」香港展商新世界海達有限公司董事長張海達亦稱今年接觸到俄羅斯、韓國及中國內地客戶,在展會的銷售表現較去年升三倍。在鑽石、寶石及珍珠展,德國展商HC Arnoldi e.K.行政總裁Carl Philip Arnoldi表示:「展會最大優勢之一是吸引全球製造商及買家參與,參展首天已接觸到許多中東和亞洲的客戶,我們預計今年銷售將有20%至50%的升幅。」另有展商表示通過展會不但接觸到美國大型零售業優質買家,亦找到新興市場如印尼、菲律賓及越南等具潛力的合作夥伴,又見許多買家重臨採購。同時,部份中國內地、中東、美國及馬來西亞的買家預計在珠寶雙展斥資數十萬至上百萬美元採購。在珠寶展,來自中國內地的湖南省彩度珠寶貿易有限公司已訂購價值超過40萬美元的高品質澳洲珍珠;來自阿聯酋的Kanz Jewels LLC已預算25 萬美元作採購之用;黎巴嫩買家Michel Zoughaib稱讚展會提供一站式平台,可採購不同設計的產品,甚至珠寶技術及包裝,預算花費100萬美元,「如覓得合適的供應商,我可把預算提高至約1,500萬美元。」美國買家David Levy Diamond Inc.總裁David Levy亦稱,在展會不但可聯繫生產商,也能接觸供應鏈中不同類型的企業,只需來香港珠寶雙展便可覓得所需一切,「相信會在鑽石、寶石及珍珠展花費20萬美元,在珠寶展預料最少花費25萬美元。」另外,有來自東盟市場買家採購態度積極,例如馬來西亞多美集團預算花費10至20萬美元採購。提升穆斯林友善採購體驗配套今年大會為鼓勵穆斯林買家來港採購,特別加強穆斯林友善措施,包括會場設祈禱室、提供接駁巴士往返清真寺、提供穆斯林友善酒店和餐廳名單、並與香港旅發局合作提供特色導賞團等,鼓勵穆斯林買家來港採購。作為全球領先的一站式珠寶業採購平台,今年珠寶雙展繼續沿用「展覽+」(EXHIBITION+)線上線下融合模式,讓企業延伸實體展中的洽商至網上智能配對平台。當中「商對易」(Click2Match)的人工智能會為展商及買家提供線上商貿配對。在場買家則可利用「掃碼易」(Scan2Match)掃描展商的二維碼,於展會期間或之後隨時隨地於線上洽談。買家亦可以通過「香港貿發局商貿平台」流動應用程式(HKTDC Marketplace App)及兩展的官方網頁,預先完成登記及認證買家證,大大提升進場及採購效率。圖片下載:https://bit.ly/3XyhcAc由香港貿發局主辦的第41屆香港國際珠寶展,以及第11屆香港國際鑽石、寶石及珍珠展圓滿結束。珠寶雙展廣受全球業內人士喜愛,買家採購態度積極。財經事務及庫務局常任秘書長(財經事務)甄美薇(右五)擔任珠寶交流酒會的主禮嘉賓,酒會接待來自海內外的珠寶業界代表、買家等,促進業界的交流合作。珠寶匯演展示最新創意設計,促進各方交流。淘寶天貓參與珠寶展,助展商突破地域界限,開拓內地市場。珠寶展增設「黃金首飾」展區,展示設計新穎的金飾。珠寶雙展設38個展館,其中亞洲珠寶文化設計工藝協會首度參展。此外,珠寶展今年新增「新晉珠寶設計師」專區,展示新生代設計師的創意及工藝。珠寶雙展期間舉行超過30場珠寶行業講座及交流活動。相關網頁 香港國際珠寶展香港國際鑽石、寶石及珍珠展展覽網頁http://hkjewelleryshow.hktdc.com/tchttp://hkdgp.hktdc.com/tc精選產品https://bit.ly/4hE1ifz香港貿發局新聞中心:http://mediaroom.hktdc.com/tc傳媒查詢香港貿易發展局傳訊及公共事務部:夏妙婷電話:(852) 2584 4575電郵:sharon.mt.ha@hktdc.org張希汶電話:(852) 2584 4272電郵:serena.hm.cheung@hktdc.org劉茸電話:(852) 2584 4472電郵:clayton.y.lawuw@hktdc.org香港貿易發展局簡介香港貿易發展局(香港貿發局)是於1966年成立的法定機構,負責促進、協助和發展香港貿易。香港貿發局在世界各地設有超過50個辦事處,其中13個設於中國內地,致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團,為企業(尤其是中小企)開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台,提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊,請瀏覽www.hktdc.com/aboutus/tc。 Copyright 2025 亞太商訊 via SeaPRwire.com.

Twin jewellery shows attract over 82,000 global buyers

- The Hong Kong International Jewellery Show drew to a successful close yesterday while the Hong Kong International Diamond, Gem & Pearl Show ended on Thursday- The twin shows attracted over 82,000 buyers from 141 countries and regions, illustrating Hong Kong’s international influence as a trading platform for the industry- There was an increase in the number of buyers from ASEAN, Middle East, Western Europe and North America.- An on-site survey revealed that buyers and exhibitors considered the Middle East market to hold the greatest potential for growth in the jewellery industry over the next two years- Over 40% of respondents expected overall sales to increase in the next one to two years, with more than 50% anticipating stabilityHONG KONG, Mar 9, 2025 - (ACN Newswire via SeaPRwire.com) - The 41st Hong Kong International Jewellery Show and 11th Hong Kong International Diamond, Gem & Pearl Show, organised by the Hong Kong Trade Development Council (HKTDC), attracted some 4,000 exhibitors from more than 40 countries and regions, running in the successful “two shows, two venues” format. The Jewellery Show concluded at the Hong Kong Convention and Exhibition Centre (HKCEC) yesterday while the Diamond, Gem & Pearl Show closed at AsiaWorld-Expo on Thursday. This year’s International Jewellery Show introduced the Gold Jewellery zone, showcasing unique designs and exquisitely crafted gold jewellery, and the Young Jewellery Designer Arena, highlighting the potential of emerging designers, helping the industry to capture new opportunities.The twin jewellery shows attracted over 82,000 buyers from 141 countries and regions. Among them, some 32,000 buyers from 125 countries and regions participated in the Diamond, Gem & Pearl Show, while about 51,000 buyers from 133 countries and regions attended the International Jewellery Show. There was an increase in the number of buyers from ASEAN, the Middle East, Western Europe and North America, highlighting the international appeal of the shows.Sophia Chong, Deputy Executive Director of the HKTDC, said: “As a leading global trading hub for the jewellery industry, the twin jewellery shows brought together international buyers and organised more than 30 industry seminars and activities to foster innovation and collaboration within the sector. The shows also actively promote local design and nurture the next generation of industry talents through jewellery design competitions, underscoring their impact on the global jewellery landscape and reinforcing Hong Kong's status as a world-class convention and exhibition centre."Exhibitors and buyers are most optimistic about the Middle East marketTo gain deeper insights into current and upcoming trends in the jewellery industry, the HKTDC conducted a survey among 1,434 exhibitors and buyers on-site. The results revealed that buyers and exhibitors are cautiously optimistic on the industry outlook. Key findings from the survey are as follows:Market and industry outlook      44.2% of respondents expected overall sales to increase in the next one to two years, with 50.6% anticipating stability.Respondents considered the growth prospects for jewellery products in the following target sales markets to be optimistic and very optimistic in the next two years: Middle East (76.8%), India (72.6%), Australia and Pacific Islands (67.8%), ASEAN (66.2%) and Korea (66.0%).In terms of market potential, the top markets most respondents wished to enter or develop were Europe (24.9%), ASEAN (15.2%), North America (13.4%), Middle East (11.4%) and Japan (7.9%).Looking ahead for the next three years, technological advancements in artificial intelligence (62.8%), big data (46.9%) and social media (44.6%) were anticipated to have the greatest impact on the jewellery industry.Product trendsRespondents believed that trendy fashion jewellery (61.9%), precious jewellery (39.1%) and demi fine jewellery (24.4%) have the greatest growth potential this year.Karat yellow gold (43.4%), karat white gold (37.8%) and pure gold (28.6%) will be the most popular precious metal products in 2025.Diamond (47.6%) will be the most in-demand gemstone, followed by ruby (26.2%) and emerald (19.1%).Echoing measures in the latest Government Budget, the twin jewellery shows continue exploring ways to facilitate local businesses expanding into the Mainland Chinese market and to seize e-commerce opportunities. This year, mainland e-commerce platforms Taobao and Tmall joined the International Jewellery Show the first time, helping exhibitors to enter the mainland market via live e-commerce. With 10 exhibitors and six KOLs participating, the event achieved a total reach of over 6 million people and generated sales of more than HK$50 million.Exhibitors reported sales exceeded expectationsThe twin jewellery shows are widely respected by the global industry, with happy exhibitors reporting that their sales exceeded expectations in 2025. Bringing together nine designers at the International Jewellery Show, the chairman of the Asia Jewelry Culture Design and Crafts Association in Hong Kong, Gigi Cheng, said: “We hope to connect with buyers from the Middle East through the show and explore new international markets, aiming for sales of US$1 million to $3 million.” Hong Kong exhibitor Hatta Chang, Chairman of Hatta New Company, stated that the company successfully connected to buyers from Russia, Korea and Mainland China with sales tripling compared to last year.   At the Hong Kong International Diamond, Gem & Pearl Show, Carl Philip Arnoldi, CEO of German exhibitor HC Arnoldi e.K, said: “One of the show’s biggest advantages is its ability to attract manufacturers and buyers from around the globe. On the first day, we received many buyers from the Middle East and Asia. We anticipate a sales growth of 20% to 50% this year.” Another exhibitor pointed out that the shows not only connected them with major retailers in the United States, but also potential partners in emerging markets such as Indonesia, the Philippines, Vietnam, and more. He also met a lot of return buyers sourcing at the shows.Additionally, buyers from Mainland China, the Middle East, the United States and Malaysia anticipated to invest sums of up to US$1 million in sourcing at the twin jewellery shows. At the International Jewellery Show, Hunan Caidu Jewelry Trading Co., Ltd from Mainland China placed an order of more than US$400,000 for high-quality pearls from Australia. Kanz Jewels LLC from the UAE budgeted to place an order worth US$250,000. Lebanese buyer Michel Zoughaib praised the show as a one-stop platform for sourcing products with different designs, as well as jewellery technology and packaging. He came with a budget of US$1 million but, “If I can find the right supplier, I can spend up to US$15 million,” he said.David Levy, President of David Levy Diamond Inc. in the United States, stated that the shows not only enabled connections with manufacturers but also provided access to different types of businesses within the supply chain. He believed that by attending the Hong Kong twin jewellery shows, he could find everything he needed. “I expect to spend US$200,000 at the Diamond, Gem & Pearl Show and at least US$250,000 at the Jewellery Show,” he said. The sourcing dynamic of buyers from the ASEAN market was noticeably vibrant, with Tomei Gold and Jewelry Manufacturing SDN BHD from Malaysia saying it had allocated a procurement budget of US$100,000 to $200,000.Enhancing support for a Muslim-friendly sourcing experienceThis year, special measures were introduced to encourage more Muslim buyers to visit the shows, including providing prayer rooms in venues, running shuttle buses to and from local mosques, offering a list of Muslim-friendly hotels and restaurants, and cooperating with the Hong Kong Tourism Board to arrange guided tours.As a globally leading one-stop jewellery industry sourcing platform, this year's twin jewellery shows continue to adopt the EXHIBITION+ online and offline hybrid format, enabling enterprises to extend their physical exhibition negotiations to online matching platforms. The HKTDC’s AI-powered Click2Match provided online business matching for exhibitors and buyers, while buyers were able to use Scan2Match to scan exhibitors’ QR codes and continue discussions with exhibitors online during or after the show. Buyers could enhance their efficiency by completing registration and buyer verification in advance through the HKTDC Marketplace App and the official show websites.Photo download: https://bit.ly/3XyhcAcOrganised by the HKTDC, the 41st Hong Kong International Jewellery Show and 11th Hong Kong International Diamond, Gem & Pearl Show have concluded successfullyThe twin jewellery shows are widely respected by the global industry and the sourcing dynamic of buyers was noticeably vibrant this yearSalina Yan, Permanent Secretary for Financial Services and the Treasury (Financial Services) of the Hong Kong SAR Government (fifth right), was Guest of Honour at the jewellery networking reception to welcome representatives and buyers from both local and international sectors with the goal of enhancing collaboration and fostering exchange within the industryThe jewellery parades showcased cutting-edge creative designs and enhanced interaction among industry stakeholdersThe participation of Taobao and Tmall at the International Jewellery Show helped exhibitors to broaden their reach in the Mainland China marketThe International Jewellery Show introduced the Gold Jewellery zone this year, showcasing innovatively designed gold jewelleryThe twin jewellery shows featured 38 pavilions with the Asia Jewellery Culture Design and Crafts Association Limited participating for the first time. In addition, the Young Jewellery Designer Arena was unveiled at this year’s International Jewellery Show, highlighting the creativity and craftsmanship of up-and-coming designersOver 30 industry seminars and networking events were held during the twin jewellery showsWebsites Hong Kong International Jewellery ShowHong Kong International Diamond, Gem & Pearl ShowWebsitehttps://www.hktdc.com/event/hkjewellery/enhttps://www.hktdc.com/event/hkdgp/enSelected productshttps://bit.ly/4hE1ifzHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact HKTDC’s Communication & Public Affairs Department:  Sharon HaTel: (852) 2584 4575Email: sharon.mt.ha@hktdc.orgSerena CheungTel: (852) 2584 4272Email: serena.hm.cheung@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lawuw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation

HONG KONG, Mar 7, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines' stock (1952.HK) surged today, opening higher and maintaining strong momentum throughout the trading day. By market close, the stock had risen 20.12% to HK$60.6, bringing the company's total market capitalization to HK$19.791 billion. This marks its highest level in nearly three and a half years since September 28, 2021, while also successfully surpassing its 2020 IPO issue price of HK$55, reflecting strong investor confidence in its AI-based mRNA platform, dual-engine strategy, and future commercialization prospects.According to the latest updates, Everest Medicines announced yesterday that the first patient has been dosed with the Company’s internally developed personalized mRNA cancer vaccine EVM16 at Peking University Cancer Hospital as part of an investigator-initiated clinical trial (IIT). Following this announcement, the company held an Investor Calls, where it provided detailed insights into its AI-based mRNA platform and pipeline advancements, highlighting progress in neoantigen prediction, vaccine development, and future commercialization strategies.Governments worldwide continue to support mRNA-based oncology research, with leading biopharmaceutical companies such as BioNTech and Moderna achieving breakthroughs in personalized cancer vaccines. Over the next one to two years, several key milestones are expected, particularly in melanoma, pancreatic cancer, and other high-mortality cancers, further reinforcing the therapeutic potential of mRNA-driven oncology treatments.Everest Medicines has established a fully integrated and clinically validated mRNA platform, encompassing antigen design, mRNA sequence optimization, LNP delivery system, and GMP production capabilities. The company holds global rights to its platform and pipeline, which is structured around four key areas: personalized cancer vaccines (PCV), tumor-associated antigen (TAA) vaccines, immune-modulatory cancer vaccines, and in vivo CAR-T therapies. With a comprehensive and differentiated portfolio, Everest Medicines is well-positioned in the rapidly evolving mRNA therapeutic landscape.The success of personalized cancer vaccines depends on the ability to identify the most immunogenic tumor mutations among thousands of genetic alterations. Everest Medicine’s proprietary machine learning based neoantigen prediction algorithm (EVER-NEO-1), uses advanced deep learning technology to precisely select highly immunogenic peptide sequences, optimizing them for mRNA vaccine design.Independent validation has shown that EVER-NEO-1’s neoantigen prediction capability meets or exceeds industry-leading standards. In head-to-head comparisons with MSKCC, a globally recognized neoantigen prediction algorithm, Everest’s model demonstrated superior performance in identifying a broader range of highly immunogenic tumor neoantigens.In preclinical studies, EVM16 demonstrated significant tumor growth inhibition in syngeneic mouse model, with repeated dosing showing favorable safety and tolerability. Preclinical data also showed a synergistic anti-tumor effect when EVM16 was combined with a PD-1 antibody, supporting its potential use in combination therapies in clinical settings.Additionally, Everest is advancing EVM14, its off-the-shelf TAA cancer vaccine, which has achieved key regulatory milestones. The company will submit an investigational new drug application for its TAA vaccines in China and the United States in 2025. One of EVM14’s key advantages is its ability to induce long-term immune memory and prevent tumor recurrence. In preclinical studies, 13 out of 15 mice treated with EVM14 experienced complete tumor regression, with no tumor regrowth even after re-exposure to tumor cells. Additionally, EVM14 has shown enhanced anti-tumor efficacy when combined with PD-1 inhibitors, further supporting its clinical potential.Everest’s mRNA platform extends beyond oncology, with the company advancing immune-modulatory cancer vaccines and in vivo CAR-T therapies. The in vivo CAR-T program, leveraging mRNA/tLNP technology, has successfully achieved T cell transfection and CAR expression in non-human primate models. Compared to conventional CAR-T therapies, Everest’s in vivo CAR-T offers significant advantages, including lower production costs, enhanced safety, no need for lymphodepletion, and potential for outpatient treatment administration. Early data also suggests promising applications in refractory systemic lupus erythematosus (SLE), demonstrating its broader therapeutic potential.Speaking at today’ s Investor Calls, Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, stated: "Everest Medicines has successfully transitioned from a license-in-driven model to a dual-engine strategy. The establishment of our proprietary mRNA platform marks a significant milestone, strengthening our in-house R&D capabilities and serving as a key driver of future growth. At the same time, we are accelerating the commercialization of our core products and remain committed to achieving our strategic goal of exceeding RMB 10 billion by 2030. Everest Medicines is poised to unlock even greater long-term value and advance toward the forefront of global biopharmaceutical innovation."From a capital markets perspective, Everest Medicines’ AI-based mRNA platform integrates cutting-edge antigen selection, mRNA sequence optimization, and industrial-scale production capabilities, positioning it as a strong player in the global mRNA therapeutics space. Everest Medicines is the first biopharmaceutical company in China to advance an AI-based personalized mRNA cancer vaccine into the clinical stage. BOCOM International has recognized Everest Medicines as a key innovator in mRNA cancer therapeutics, highlighting its strong pipeline catalysts, significant revenue potential, and substantial valuation upside. Everest is well-positioned to strengthen its leadership in AI-enabled mRNA innovation and drive new global collaborations in the biopharmaceutical sector. Copyright 2025 ACN Newswire via SeaPRwire.com.

OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million

Results Highlights:- Revenue hit record high of US$164.1 million, up 6.6% year-on-year.- Sales volume reached 1.7 million units, of which 1.5 million units were proprietary products, showing an increase of 4.8% year-on-year.- Gross profit increased by 7.5% to US$114.5 million, with gross profit margin improving to 69.8%; profit for the year attributable to owners of the Company was US$39.7 million.- The Board proposed a final dividend of HK10 cents per share, representing a dividend payout ratio of 26.7%.- The Group maintained a sound financial position with cash and bank balances of US$248.6 million at year-end to support merger and acquisition initiatives.- Fueled by newly acquired distributors in Indonesia and South Korea, along with organic growth in direct sales, APAC market revenue grew 43.7% year-on-year, while the US and the PRC markets showed signs of recovery in the second half of 2024.- The Group registered products of eucatech AG, a German company acquired in November 2023, in the Czech Republic, Italy, Malaysia, Saudi Arabia, Spain, Switzerland, UAE, and Vietnam.HONG KONG, Mar 7, 2025 - (ACN Newswire via SeaPRwire.com) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its annual results for the year ended December 31, 2024 (the “Year”), reporting record-high revenue and healthy net profit despite the challenging business landscape.Driven by the recovery of sales in the US and continued growth in the APAC market in the second half of the year, the Group’s revenue reached US$164.1 million, an increase of 6.6% over the previous year. Excluding the impact of foreign exchange, revenue growth would have been 8.7% year-on-year. Gross profit increased by 7.5% to US$114.5 million, and gross profit margin rose slightly to 69.8%. During the Year, the Group laid the groundwork for stronger long-term performance by integrating the businesses of the three companies acquired in late 2023. Although these integration efforts incurred temporary costs, resulting in a profit of US$39.7 million attributable to the owners of the Company (2023: US$45.1 million), they are expected to generate substantial synergies in the future. Excluding the abovementioned additional expenses, the three core operating expenses, namely selling and distribution expenses, general and administrative expenses and research and development expenses, were remained stable year-on-year.As of December 31, 2024, the Group was in a strong financial position with cash and bank balances amounting to US$248.6 million (2023: US$255.8 million). After careful consideration of the Group’s future capital requirements, the Board has proposed a final cash dividend of HK10 cents per share (2023: HK10 cents per share) as a token of appreciation for the continued support from shareholders and investors.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “In 2024, the OrbusNeich team navigated challenges while diligently strengthening R&D, production, supply chain, clinical, regulatory, quality, sales, and marketing capabilities. The immediate contributions of our newly acquired distributors in Indonesia and South Korea bolstered our APAC market performance. Meanwhile, our focus on product registration for eucatech AG, has resulted in approvals in eight countries, with more on the horizon. As we celebrate OrbusNeich’s 25th anniversary in 2025, our relentless innovation, strong global presence and pioneering products will continue to propel us to new heights, as evidenced by our established global reputation and continued revenue growth over the past few years. Looking ahead, we remain committed to improving patient outcomes while striving to create long-term value for shareholders.”Extensive Sales Network Fuels Growth in APAC and EMEAOrbusNeich sold its products through its extensive sales network covering more than 70 countries and regions worldwide, and maintained a balanced revenue distribution across major markets. Driven by external growth from newly acquired distributors in Indonesia and South Korea, as well as robust organic growth from the markets in Malaysia, Singapore, Hong Kong, Vietnam, and India, the APAC market became the Group’s major growth driver during the Year, with revenue increasing by 43.7% to US$52.2 million. In particular, the latest generation of scoring balloon, Scoreflex TRIO, recorded rapid sales growth following its launch in Malaysia in early 2024. EMEA market revenue grew by 7.9% year-on-year to $39.2 million, mainly attributable to increased sales of the Group’s proprietary balloon products in direct sales markets such as Germany and Spain, as well as in distribution markets such as the Czech Republic, Slovakia, and the United Kingdom.Both the PRC and the US markets achieved significant improvement in the second half of 2024. As the Beijing-Tianjin-Hebei “3+N” Alliance Volume-Based Procurement (“VBP”) was gradually rolled out in various provinces, the Group adopted a more proactive marketing strategy, which resulted in Scoreflex’s sales volume gaining momentum, facilitating an improvement in the performance of the PRC market in the second half of the year, reaching a revenue of US$20.7 million. Meanwhile, following active discussions with Abbott, the Group’s US distributor, revenue in the US gradually picked up. In particular, the sales volume of the high selling price product, Scoreflex NC, more than tripled in the second half of the year compared with the first half, driving the revenue of the US market to reach US$17.5 million. The Japan market recorded revenue of US34.4 million.Diversity in Innovation with a Portfolio of Approved Products and Upcoming Clinical TrialsAs of December 31, 2024, OrbusNeich had more than 240 granted patents and published patent applications worldwide in key jurisdictions and an aggregate of more than 50 approved products. During 2024, the Group made significant progress in terms of product registrations and clinical trials, including:- Obtained NMPA approval for Teleport Neuro, FDA approval for Teleport XT, JADE PLUS 14/18/35 OTW, Sapphire Ultra and Sapphire NC Ultra, and CE Marks for Sapphire Ultra, Sapphire NC Ultra, Xtenza and Teleport XT;- Submitted NMPA registration application for its guiding catheter and Jade PTA Line Extension, and PMDA registration application for Scoreflex QUAD and Teleport Glide;- Completed clinical trial patient enrollment for Scoreflex TRIO in the PRC with NMPA application submission in January 2025;- Initiated clinical trial patient enrollment for Sapphire 3 in the US in Q4 2024, with approval application expected to submitted in Q1 2026.The Group has also been actively registering eucaLimus (DES), Support C (coronary DCB), and VITUS (peripheral DCB) in various countries following the acquisition of eucatech AG in late 2023. Registrations for one or more of the above-mentioned products were completed in the Czech Republic, Italy, Malaysia, SaudiArabia, Spain, Switzerland, the UAE, and Vietnam, while applications are pending approval in Hong Kong, Indonesia, and Singapore. Additionally, to renew the CE Mark for its products under the MDR regime, clinical registries have been initiated with renowned key opinion leader clinicians as lead principal investigators.The Group continued to invest in new pipeline products such as the aspiration catheter, dual lumen catheter, peripheral scoring balloon and sheath, and registration of these products is expected to be submitted to various regulatory bodies in 2025. In line with the “leave nothing behind” trend, the Group is also investing in proprietary paclitaxel DCB, with clinical trials expected to commence in the fourth quarter of 2025 in Japan.During the year, the joint venture OrbusNeich P&F made significant efforts to advance the clinical studies of TricValve in two major APAC markets. The clinical trial in the PRC started in April 2024, while the PMDA clinical trial protocol approval in Japan is expected to be completed by the end of 2025.In addition to proprietary products, the Group also entered into a distribution agreement with a Chinese manufacturer to distribute its intravascular ultrasound (IVUS) catheter in Hong Kong and Macau from December 2024, thereby diversifying its product offerings.Exceptional Product Quality Ensured through Stringent Production ProcessesAs of December 2024, OrbusNeich’s annual production capacity reached approximately 2.0 million units of balloons and 60,000 units of stents, with product quality ensured by a strict management system and maintaining ISO 13485 certification. Notably, eucatech AG successfully passed its ISO 13485 re-certification audit in the latter half of 2024, while the Shenzhen site achieved ISO 14001 and ISO 45001 certifications in June 2024, highlighting its commitment to sustainability.In addition, the construction of the Group’s largest R&D and production facility in Hangzhou, PRC, progressed smoothly during the Year. The Group is currently focusing on enhancing its automation levels to reduce labor requirements, improve operational efficiency, and ultimately lower overall operating costs. The facility is expected to be operational in 2027 and will add an annual production capacity of 2.4 million units upon the commencement of production.Mr. Chien concluded, “Entering 2025, we are cautiously optimistic about our prospects given the strong growth momentum in APAC and EMEA, as well as the recovering US and PRC markets. Over the past 25 years, our success has been fueled by continuous innovation, product line expansion and a strengthened sales network. These efforts, together with the synergies from the integration of our acquired businesses, will position us well to capitalize on the opportunities that lie ahead. With robust financial resources, we are able to take advantage of industry consolidation for strategic mergers and acquisitions to enhance our technological reserves and expand our product portfolio. To maintain our steady growth in the medical device market, we will place greater emphasis on sustainable development to adapt to the evolving healthcare landscape while staying true to our mission of improving patient outcomes.”About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/. Copyright 2025 ACN Newswire via SeaPRwire.com.

uSMART Securities Initiates Coverage on NAAS Technology with a ‘Buy’ Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook

HONG KONG, Mar 7, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities recently initiated coverage on NAAS Technology Inc. (NASDAQ: NAAS) with a “Buy”rating, setting a target price of US$3.20 per ADS, compared to the current trading price of US$1.15 per ADS as of March 7, 2025. The firm’s investment thesis is driven by the following key factors:1. Industry Leadership in the EV Charging PlatformNAAS is a leading electric vehicle (EV) charging platform in China, boasting a strong market presence in both network scale and user base. As of Q3 2024, the company had connected approximately 100,000 charging stations and 1.15 million chargers, accounting for 35% of the total public chargers in China. its platform served approximately 14 million transaction users, covering 50% of the country’s EV owners. In Q3 alone, NaaS facilitated 1.3 billion kWh of charging volume and 50 million transactions. With its robust supply and demand integration, uSMART Securities expects NaaS to further enhance network efficiency and maintain its market leadership.2. Profitability Breakthrough through an Asset-Light Business ModelNAAS’s strategic focus on asset-light, platform-based business model is accelerating the path to profitability. In 2024, the company shifted its focus to platform-based charging interconnectivity services, leading in substantial margin growth. Gross profit margin surged from 19% in 4Q 2023 to 57% in 3Q 2024, while non-IFRS net profit margin improved dramatically from -525% to 46% over the same period. This accelerated NAAS’ path to profitability ahead of schedule. Looking ahead, as economies of scale continue to expand, NAAS is expected to further improve its financial performance, transitioning from a cash-burning startup into a fundamentally driven growth company.3. AI- Driven Data Monetization OpportunitiesNAAS is uniquely positioned to capitalize on data monetization in the AI era. With 35% of public chargers and 50% of EV users in China, the company has developed the NAAS Energy Fintech (NEF) system, leveraging proprietary AI algorithms to explore potential opportunities:- Dynamic Pricing: Adjusts service fees in real-time based on demand and electricity prices, enhancing price elasticity and increasing customer retention.- Intelligent Asset Management: Uses AI-driven site selection and real-time monitoring to improve charging station efficiency and utilization.- Grid Load Balancing: Supports governments and regulators in peak shaving and demand responseWith China's EV adoption accelerating into 2025, NAAS is poised to further explore commercialization opportunities in these areas.4.  Attractive Valuation Amid Sustainable ProfitabilityNaaS presents a compelling valuation, particularly as it approaches full-year break-even in 2025. This shift in profitability allows for a transition in valuation methodology from a startup-focused P/S ratio to a broader mix of P/S, PEG, and P/E multiples. Based on projected 2025 revenue of RMB 229 million and a 1.4x P/S ratio aligned with US-listed peer companies, uSMART Securities gives NAAS a “Buy” with a target price of US$3.20 per ADS. Copyright 2025 ACN Newswire via SeaPRwire.com.

Chery Auto Launches an IPO on HKEX – Fundamentals Driving Long-term Value Growth

HONG KONG, Mar 5, 2025 - (ACN Newswire via SeaPRwire.com) - Since 2024, the Chinese automotive industry has witnessed a wave of domestic brands replacement. With the dual drivers of the booming new energy vehicle market and sustained national policy support, domestic brands have achieved significant advances against international brands by means of new energy transformation, coordinated efforts in domestic and international markets, technological innovation, and global expansion, resulting in a continuous increase in market share. As Chinese domestic passenger car brands rise in the global market, the capital market is likely to recognize the intrinsic value of Chinese automakers. Chery Automobile, which submitted its application to the Hong Kong Stock Exchange on February 28, 2025, presents a unique investment opportunity.Founded in 1997, Chery Automobile has long led the industry in innovation and deep international market penetration, achieving comprehensive global business coverage and industry-leading sales. This has cemented its solid position in China's domestic passenger car market. According to Frost & Sullivan, based on global sales for the nine months ended September 30, 2024, Chery Automobile is the second-largest domestic passenger car company in China and 11th largest passenger car company globally.Reinforced Innovation to Establish Core Technological CompetitivenessUpholding the development philosophy of “Building the Enterprise through Technology,” Chery Automobile has been always regarding technological innovation as the core of its business growth. The Company has established a multi-tier and comprehensive R&D system, including the Kaiyang collaborative research initiative, Stellar Lab (core technology research and development platform), and research and development centers located in China, Europe, South and North America, and Southeast Asia.Supported by this robust R&D system and strong research capabilities, Chery Automobile has pursued a technology strategy of “Dual Strategy of ICE (internal combustion engine) vehicles and NEVs,” and achieved technological synergies between ICE vehicle and NEV models. In the field of ICE technology, the Company produced China’s first self-develop proprietary ICE engine for passenger vehicle in 1999; its in-house developed Chery Power 8-speed automatic transmission was the first proprietary 8AT transmission with full intellectual property rights in China. In the field of new energy vehicle hybrid system technology, the Company’s high-performance hybrid engine boasts industry-leading thermal efficiency and the REEV engine can achieve an oil-to-electricity conversion efficiency of 3.7 kWh/L, ranking among the best in the industry, while its hybrid DHT’s maximum mechanical efficiency in pure electric mode is among one of the highest globally.To promote intelligence technologies for NEVs to the next level and accelerate the adoption of intelligence solutions for ICE vehicles, Chery Automobile is committed to providing cost-effective intelligence solutions to users of both ICE vehicles and NEVs, such as its intelligent cockpit system and applications featuring smooth connectivity, personalized intelligence and comprehensive functions across China and overseas markets. In the first nine months of 2024, the percentage of its passenger vehicles equipped with L2 and above intelligent driving solutions reached 50.7%.Rapid Growth Supported by a Diverse Shareholder BasePowered by its exceptional technological advantages, Chery Automobile's diverse range of models has gained widespread market approval, resulting in soaring sales. In the first nine months of 2024, the Company's passenger car sales increased by 51.8% compared to the same period in 2023, leading the growth among the world's top 20 passenger car companies. Moreover, Chery Automobile was the only passenger vehicle company among the global top 20 to achieve a sales volume increase over 30.0% for both NEVs and ICE vehicles and in both China and overseas markets.The rapid business growth has translated into outstanding financial performance. In the first nine months of 2024, Chery Automobile achieved revenues of approximately RMB 182.154 billion, marking a 67.7% year-on-year increase. Net profit reached about RMB 11.312 billion, a year-on-year growth of 58.5%. The return on equity (ROE) was 81.6%. As of September 30, 2024, the Company had cash and cash equivalents totaling RMB 41.938 billion, indicating robust capital reserves.Previously, Chery Automobile has gone through several rounds of strategic financing, forming a diversified shareholder layout. This includes state-owned entities such as Anhui Credit Financing Guaranty Group Co., Ltd., Wuhu Investment Holding Co., Ltd., Bohai Industrial Investment Fund Management Co., Ltd., Qingdao Urban Investment International Development Group Co., Ltd., and Changshu Port Development Construction Co., Ltd., as well as renowned publicly-listed companies and investment institutions like Luxshare Investment (HK) Limited, CATL, Gotion High-Tech, and so on, providing substantial financial and resource support to the Company.In 2024, Chery Automobile's outstanding performance in multiple dimensions, including sales volume, revenue, profit, new energy vehicles, fuel vehicles, and exports, has accumulated sufficient momentum for landing on the international capital market.  A Hong Kong listing will not only help the Company establish a long-term capital replenishment channel but also benefit the activation of its equity incentive mechanism to maximize its value potential. Copyright 2025 ACN Newswire via SeaPRwire.com.

雲頂新耀股價創3年新高 AI+mRNA賦能管線重塑估值

香港, 2025年3月7日 - (亞太商訊 via SeaPRwire.com) - 今日,雲頂新耀(1952.HK)股價強勢上漲,高開後持續走強,全天維持上升趨勢,截至收盤上漲20.12%,報60.6港元,公司總市值攀升至197.91億港元。創下自2021年9月28日以來的近三年半新高,並成功突破2020年IPO發行價55港元。據最新消息,雲頂新耀於昨日宣佈其自主研發的mRNA個性化腫瘤治療性疫苗(PCV)EVM16在中國完成首例患者給藥,該疫苗正在開展研究者發起的臨床試驗(IIT)。在這一進展公佈後,雲頂新耀隨後召開中英文投資者交流會,詳細介紹AI賦能mRNA平台的技術突破及研發管線最新動態,重點展示公司在新抗原預測、疫苗開發及未來商業化方面的最新進展。近年來,全球對mRNA技術在癌症治療中的應用給予高度關注,多國政府相繼出台政策支持該領域發展。以BioNTech、Moderna為代表的企業已在個性化腫瘤疫苗領域取得突破,預計未來1-2年將迎來多個重要里程碑,尤其是在黑色素瘤、胰腺癌等高難度癌症治療中的應用,進一步驗證了mRNA癌症疫苗的潛力。雲頂新耀已建立本地化、經臨床驗證的mRNA平台,涵蓋從抗原設計、mRNA序列優化、LNP遞送技術到GMP生產的全產業鏈能力,並擁有全部全球權益。基於該平台,公司佈局了個性化腫瘤治療性疫苗(PCV)、腫瘤相關抗原疫苗(TAA)、免疫調節腫瘤疫苗和自體生成CAR-T四大研發方向,整體佈局完備,具備顯著的差異化競爭力。EVM16作為雲頂新耀個性化腫瘤治療性疫苗(PCV)的代表性項目,已在北京大學腫瘤醫院完成首例患者給藥。其核心優勢在於雲頂新耀基於深度學習的自研新抗原預測算法-「妙算」系統(EVER-NEO-1)來篩選新抗原,可精准篩選高免疫原性肽段,優化mRNA疫苗抗原設計,提升免疫應答效果。獨立驗證顯示,EVER-NEO-1的新抗原預測能力達到或超越行業領先水準,並在頭對頭研究中優於MSKCC算法,可識別更多具備強免疫原性的腫瘤新抗原。臨床前研究表明,該算法預測的新抗原可有效激發T細胞免疫,並在小鼠腫瘤模型中展現更優療效。此外,EVM16與PD-1抗體聯合使用可增強T細胞活化,產生協同抗腫瘤作用,為未來聯合免疫療法提供了有力依據。在猴子非人靈長類實驗中,EVM16展現劑量依賴性免疫原性,加強針可進一步增強免疫應答並維持長期免疫保護,同時在臨床前毒理研究中展現良好安全性。除EVM16外,雲頂新耀正在推進現貨型TAA癌症疫苗EVM14的臨床開發,並計劃於2025年在中美兩地遞交新藥臨床試驗申請。EVM14的一大突破在於可誘導免疫記憶,防止腫瘤復發。在動物實驗中,13/15只小鼠在EVM14治療後腫瘤完全消退,即使再次接種腫瘤細胞,仍未出現復發,驗證了其長期保護作用。同時,EVM14在聯合PD-1抗體使用時展現出更強的抗腫瘤活性,進一步支持其在臨床應用中的潛力。雲頂新耀的mRNA平台還覆蓋免疫調節腫瘤疫苗和自體生成CAR-T。其中,自體生成CAR-T療法基於mRNA/tLNP平台,可在體內直接生成CAR-T細胞,突破傳統CAR-T的局限性。相較于傳統CAR-T療法,mRNA體內CAR-T具有更低的生產成本、更高的安全性、無需清除淋巴、不依賴住院治療等優勢。此外,該技術還在系統性紅斑狼瘡(SLE)等自身免疫疾病中展現潛力,為CAR-T療法拓展至非腫瘤適應症提供了全新可能。雲頂新耀CEO羅永慶在今日投資者交流會上表示:「雲頂新耀已成功從依賴授權引進(license-in)的模式,轉型為自主研發與授權引進並行的雙輪驅動模式,建立了具有自主知識產權的mRNA平台。這一里程碑不僅強化了公司的自研創新能力,也將成為未來增長的重要引擎。與此同時,我們正加速推進核心產品的商業化進程,並堅定執行2030年前核心產品銷售突破100億元人民幣的目標。隨著mRNA平台和自體生成CAR-T療法的持續突破,雲頂新耀的長期價值將進一步釋放,助力公司邁向全球生物醫藥創新的前沿。」從資本市場的角度來看,雲頂新耀的mRNA平台整合了AI驅動的抗原篩選、mRNA序列優化及產業化能力,具備較強的全球競爭力和商業化潛力。雲頂新耀是國內首個將由AI驅動的mRNA腫瘤治療性疫苗進入臨床階段的生物製藥公司。交銀國際在研報中重點推薦雲頂新耀,認為其創新管線催化劑豐富,盈利增長潛力明確,具備較大的估值修復彈性。隨著EVM16的臨床推進、EVM14的全球化申報進展以及體內CAR-T療法的持續突破,雲頂新耀的AI+mRNA佈局不僅強化了其行業領先地位,也有望成為國際BD合作的重要籌碼,在全球創新藥競爭格局中佔據更有利的位置。 Copyright 2025 亞太商訊 via SeaPRwire.com.

業聚醫療連續四年實現收入增長 達1.64億美元創新高 純利達3,970萬美元 建議派發末期股息每股10港仙

業績亮點:- 收入同比增長6.6%達164.1百萬美元創新高。- 銷量達1.7百萬件,其中1.5百萬件為自有產品,同比增長4.8%。- 毛利上升7.5%至114.5百萬美元,毛利率提升至69.8%;公司擁有人應佔利潤達39.7百萬美元。- 董事會建議派發末期股息每股10港仙,派息比率為26.7%。- 集團的財務狀況穩健,年末現金及銀行結餘為248.6百萬美元,擁有充足資金支持日後的併購計劃。- 在新收購的印尼及韓國分銷商推動下,加上來自直銷業務的內生增長,亞太區市場收入同比增長43.7%,而美國及中國市場亦於2024年下半年呈現復甦跡象。- 集團於2023年11月收購德國公司eucatech AG後,已為其產品在捷克、意大利、馬來西亞、沙特阿拉伯、西班牙、瑞士、阿聯酋及越南完成註冊。香港, 2025年3月7日 - (亞太商訊 via SeaPRwire.com) - 專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929)今天宣佈截至截至2024年12月31日止年度(「年度」)的全年業績。儘管業務環境充滿挑戰,但集團仍創下收入新高,並錄得穩健純利。受到下半年美國市場銷售回升,以及亞太區市場的持續增長帶動,集團的收入達164.1百萬美元,較去年增長6.6%。若撇除匯兌的影響,收入更同比增長8.7%。毛利上升7.5%至114.5百萬美元,毛利率亦微升至69.8%。回顧年度內,集團積極整合在2023年底收購的三間公司的旗下業務,為長遠達到理想業績奠定基礎。儘管相關整合工作短暫產生額外費用,導致公司擁有人應佔利潤錄得39.7百萬美元(2023年:45.1百萬美元),然而這些工作預計能於未來創造顯著的協同效應。撇除上述的額外開支,集團的三大核心經營開支,包括銷售及分銷開支、一般及行政開支以及研發開支,維持在與去年相若的水平。於2024年12月31日,集團的財務狀況穩健,現金及銀行結餘達約248.6百萬美元(2023年:255.8百萬美元)。經審慎評估集團未來資金需求後,董事會建議派發末期現金股息每股10港仙(2023年:每股10港仙),以答謝股東及投資者一直以來的支持。業聚醫療董事長、執行董事兼首席執行官錢永勛先生表示:「2024年,業聚醫療團隊迎難而上,在強化研發、生產、供應鏈、臨床、監管、質量、銷售及市場推廣等領域不遺餘力。其中,我們在印尼和韓國新收購的分銷商迅速為集團帶來貢獻,推動了我們在亞太市場的表現。與此同時,我們也專注於eucatech AG的產品註冊工作,並取得八個國家註冊批准,並將會在更多國家取得進展。2025年將迎來業聚醫療成立25週年。過去,我們已成功在全球市場建立了良好聲譽,以及持續數年達到收入增長。憑藉不懈的創新、強大的全球佈局以及領先的產品組合,我們有信心能再創高峰。展望未來,我們會繼續致力改善患者的治療效果,同時為股東創造長遠價值。」廣泛的銷售網絡推動亞太地區及歐洲、中東及非洲地區增長業聚醫療透過覆蓋全球70多個國家和地區的廣泛銷售網絡銷售產品,並在主要市場保持均衡的收入比例。受惠於印尼及韓國新收購的分銷商帶來的外部增長,以及馬來西亞、新加坡、香港、越南及印度市場的強勁內生增長,亞太區市場於回顧年度成為集團的主要增長動力,收入增加43.7%至52.2百萬美元。其中,最新一代刻痕球囊Scoreflex TRIO自2024年初在馬來西亞推出後,銷量迅速攀升。此外,來自歐洲、中東及非洲的收入同比增長7.9%,達到39.2百萬美元,主要由集團的自有球囊產品在直銷市場(如德國及西班牙)以及分銷市場(如捷克、斯洛伐克及英國)的銷量增長帶動。中國內地及美國市場於2024年下半年均取得顯著改善。隨著京津冀「3+N」聯盟帶量採購(「帶量採購」)在各省陸續推行,以及集團採取更積極的營銷策略,Scoreflex的銷量增長勢頭良好。因此,下半年中國市場的表現有所改善,全年收入達到20.7百萬美元。同時,在集團與美國分銷商雅培進行積極商討後,美國市場的收入逐漸回升。 尤其是高售價產品Scoreflex NC,其下半年的銷量為上半年的逾三倍,帶動美國市場的收入達到17.5百萬美元。日本市場的收入則為34.4百萬美元。多元化創新產品:涵蓋獲批及即將進行臨床試驗階段的產品截至2024年12月31日,業聚醫療在全球主要司法管轄區擁有超過240項授權專利及公佈專利申請,並擁有逾50款獲批產品。於2024年,集團在產品註冊及臨床試驗方面取得重大進展,包括:- Teleport Neuro獲得國家藥監局批准,Teleport XT、JADE PLUS 14/18/35 OTW、Sapphire Ultra及Sapphire NC Ultra 獲得FDA批准;以及Sapphire Ultra、Sapphire NC Ultra、Xtenza和Teleport XT獲得CE標誌;- 向國家藥監局提交導引導管及Jade PTA型號擴充的註冊申請,及向PMDA提交Scoreflex QUAD及Teleport Glide註冊申請;- 在中國境內進行的Scoreflex TRIO臨床試驗已完成病人入組,並於2025年1月向國家藥監局提交申請;- 於2024年第四季在美國展開Sapphire 3臨床試驗的病人入組,預計將於2026年第一季提交申請批准。繼2023年底收購eucatech AG後,集團積極在多個國家為其產品eucaLimus(藥物洗脫支架)、Support C(冠狀動脈藥物塗層球囊)及VITUS(外周藥物塗層球囊)辦理註冊。上述一種或多種產品已於捷克、意大利、馬來西亞、沙特阿拉伯、西班牙、瑞士、阿聯酋及越南等地完成註冊,而於香港、印尼及新加坡的註冊申請亦有待批准。此外,為了在MDR制度下為上述產品續領CE標誌,集團已開展臨床登記,並聘請國際知名的關鍵意見領袖(「KOL」)臨床醫師擔任該等登記的首席調查專家。同時,集團繼續投資於新產品管線,例如抽吸導管、雙腔導管、外周刻痕球囊及鞘管,並預期於2025年向各監管機構提交該等產品的註冊申請。為迎合「介入無植入」的趨勢,集團亦投資於自有紫杉醇藥物塗層球囊,預計於2025年第四季在日本展開臨床試驗。本年度,合資企業OrbusNeich P&F致力推進TricValve在亞太區兩大市場的臨床研究。在中國境內的臨床試驗已於2024年4月開始,而在日本的PMDA臨床試驗方案批准預計將於2025年底完成。除自有產品外,集團與一家中國製造商訂立分銷協議,自2024年12月起在香港及澳門分銷其血管內超聲波(IVUS)導管,從而令產品組合更為多元化。嚴格的生產程序確保卓越產質截至2024年12月,業聚醫療的球囊年產能達約2百萬件,支架年產能達約60,000件,並採用嚴格的品質管理系統及維持ISO 13485,以保障產品品質。其中,eucatech AG於2024年下半年通過ISO 13485再認證審核,而深圳基地亦於2024年6月取得ISO 14001及ISO 45001認證,突顯集團對可持續發展的承諾。此外,集團於中國杭州建設旗下最大研發及製造設施的工程於年內進展順利。集團目前致力提升其自動化水平,以減低勞動力需求及提高營運效率,最終降低整體營運成本。新設施預計於2027年投產,投產後產品年產能將增加2.4百萬件。錢先生總結:「展望2025年,有見亞太地區和歐洲、中東及非洲地區增長強勁,加上美國及中國市場持續復甦,我們對集團的前景保持審慎樂觀。過去25年,我們的成功基石建立在持續創新、拓展產品線及鞏固銷售網絡之上。這些努力,加上整合收購業務帶來的協同效應,讓我們準備就緒,把握未來的商機。我們的財政實力雄厚,也將有助我們把握行業整合的機遇,進行策略併購,藉此增強技術儲備及擴大產品組合。為了在醫療器械市場中達到穩定增長,我們將更重視可持續發展,以迎合瞬息萬變的醫療行業格局,同時貫徹實踐改善患者治療效果的使命。」關於業聚醫療集團控股有限公司業聚醫療是一家主要的全球醫療器械製造商,專門生產用於經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)的介入器械。本集團總部位於中國香港,產品銷往全球超過70個國家和地區。集團亦積極將業務擴展至神經血管介入及結構性心臟病領域。憑借擁有逾20年產品開發經驗的內部研發團隊,本集團已開發出世界領先的專有技術。如需瞭解詳情,請訪問集團官網:https://orbusneich.com/ Copyright 2025 亞太商訊 via SeaPRwire.com.

東信營銷科技:中國AI營銷龍頭斬獲多模態雙備案 技術實力獲國家級認證

香港, 2025年3月7日 - (亞太商訊 via SeaPRwire.com) - 3月6日晚間,中國AI營銷龍頭 - 東信營銷科技(以下簡稱「東信」)宣佈集團旗下「營賽洞見」多模態大模型已正式通過廣東省互聯網資訊辦公室(簡稱「網信辦」)生成式人工智能服務備案審批,成為國內首個通過多模態備案的營銷垂直大模型。此前該模型已於2024年4月獲中央網信辦大模型備案,此次多模態備案的達成,意味著東信營銷科技成為行業首個實現了大模型「雙備案」的AI營銷公司。此次雙重備案標誌著東信營銷科技在技術合規性、安全性及應用價值等方面獲得國家權威認可。根據《生成式人工智能服務管理暫行辦法》,備案審批是對大模型技術安全合規、技術能力及社會價值的重要認證。通過雙重備案的企業將具備行業准入資質,可加速技術商業化進程。備案已成為行業准入門檻,率先通過備案的企業可搶佔市場先機。通過備案後,依託營賽洞見的多模態生成能力,東信營銷科技有望加速MAA營銷智能體和MarRAG技術的研發迭代,強化自身在AI營銷領域的技術壁壘,吸引更多客戶和生態夥伴,加速行業合作與應用落地從而產生規模化經濟效益。大模型技術實力獲國家認可多模態備案是指對能夠在處理和交互中綜合運用文本、圖像、聲音等不同數據類型的人工智能模型進行官方認證和備案的過程。東信營銷科技的「營賽洞見」大模型在獲得國家網信辦多模態備案的過程中,展現了卓越的技術實力。通過備案不僅標誌著大模型在技術上的成熟,亦代表著其符合國家關於數據安全、隱私保護等方面的高標準要求。東信「營賽洞見」大模型在數據、場景、模型、算力四大核心領域擁有顯著優勢。1.數據優勢:基於2300億行業數據,高質量數據處理和高精度計算,打造大規模、高質量的營銷垂域大數據資產庫。2.場景優勢:覆蓋300+品類的全鏈路營銷場景,支撐分析洞察、內容策劃、內容生成、營銷策略等152個AIGC應用場景。3.模型優勢:7大類77個算法模型搭載五大技術中台,構成強大、高效、精准的營銷垂域技術底座。4.算力優勢:調用華為雲的鯤鵬(昇騰)架構提供強大算力和高精度計算,確保大模型在實際應用中的穩定性、可靠性。深耕AI營銷,助力企業產業升級營賽大模型憑藉卓越的多模態生成能力、AI技術實力、行業大數據支撐及完善的安全管理體系,在已通過中央網信辦備案的超302個生成式AI大模型中脫穎而出,成為率先通過備案的垂直領域AI營銷大模型。本次成功通過多模態備案,不僅顯示了公司在AI營銷領域的競爭力,也成為了其他垂直領域大模型的技術典範。據了解,東信AI營銷大模型的圖像模態技術曾在第十五屆中國航展中得到全面應用,為航展的宣傳報導注入了AI先鋒視覺和多元風格,成為航展創意海報背後的「黑科技」。以營賽洞見為代表的營銷垂直大模型的應用,不僅能為企業帶來更多元、更高效的營銷手段,也為整個行業的創新發展注入了新的活力。國家「人工智能+」戰略的推進,為AI技術落地帶來了顯著的政策紅利。隨著更多企業通過備案,大模型競爭將從「參數比拼」轉向「應用深耕」。東信集團首席架構師盧工表示:「備案不是終點,而是AI賦能客戶營銷增長的起點。唯有技術與創新並重,才能贏得長遠發展。」伴隨人工智能技術的不斷發展和完善,東信營銷科技的營賽洞見AI營銷大模型有望在更多行業中得到應用和推廣,為各行業的智能化轉型和發展帶來新的機遇和動力。 Copyright 2025 亞太商訊 via SeaPRwire.com.

世界備份日將至 – Synology群暉科技發表全新的資料保護解決方案 提升香港企業級資料韌性

圖1. Synology 群暉科技 在香港發布全新ActiveProtect 備份專用一體機。圖片下載:http://bit.ly/3FmNlo0香港, 2025年3月7日 - (亞太商訊 via SeaPRwire.com) - Synology 群暉科技針對香港企業資料保護市場,推出ActiveProtect備份專用一體機,助力企業快速部署,提升資料防護能力,應對勒索病毒攻擊、資料洩漏及業務中斷風險。隨著世界備份日的臨近,Synology群暉科技也呼籲中型至大型企業需要更積極防範資料損失、洩漏和勒索病毒的事件發生。作為私有雲解決方案的領導者,Synology 已獲全球逾半數《財富》500 強企業信賴,管理超過 520 EB(艾位元組)數據,覆蓋 1300 萬部伺服器,並累積保護超過2500萬個工作負載,不僅為業界私有雲龍頭,也確各產業的業務連續性及資料儲存安全性。香港企業資料安全形勢嚴峻 急需強化防護2024年,香港不少企業頻繁遭受網絡攻擊,導致大量個人資料外洩,當中有非牟利機構遭遇黑客攻擊,引致大量數據被盜取,受影響的個人資料更以數十萬計。同年,亦有私營機構遭勒索軟件入侵,導致大量客戶及 內部員工資料資料遭到洩漏。這些事件突顯企業需建立完善的資料備份與防護機制,以防範網絡威脅。ActiveProtect備份專用一體機:企業級資料安全,資料韌性一次到位面對日益增長的網絡安全威脅及資料管理複雜性,Synology 對此提出全新的資料保護解決方案 - ActiveProtect備份專用一體機。這可為企業打造高效、簡便、經濟的資料保護方案。其產品功能將從以下三大核心能力切入:強化勒索病毒防護透過先進安全協議確保數據不可變性,並利用氣隔備份(air-gapped backup)隔離數據,防範惡意篡改與未經授權存取。集中化管理與監控透過單一管理介面監控多達 150,000 個工作負載,統一管理備份策略、執行異地存取及還原,提升資料管理效率。極致成本效益相較傳統解決方案,ActiveProtect 的實施成本僅為 20%,更提供三部伺服器的免費授權,降低企業資料保護門檻。Synology資深區域銷售經理Suk Mi Eun 表示:「資料是企業最重要的資產,而打造具備永續的資料韌性環境更尤其重要。」他進一步指出:「企業對可擴展、安全、易用的備份解決方案需求從未如此迫切,ActiveProtect 備份專用一體機正是為此而生。我們期待這款產品能幫助香港企業更輕鬆地保護他們最有價值的資產。」高效還原能力 確保業務不中斷本次發表會現場,Synology 展示了 ActiveProtect 的資料即時還原能力,涵蓋日常故障修復至災難應對,確保企業能夠迅速恢復運營,降低停機時間,保障關鍵業務穩定運行。簡化部署 擺脫傳統備份困境傳統備份方案通常涉及多種硬件設備及複雜授權機制,導致高昂軟件成本及難以預測的儲存開銷。ActiveProtect備份專用一體機以節點為基礎的授權模式,三部伺服器可免費授權,使企業能更精確掌控成本並同時獲得可靠、安全的的資料保護,確保為香港企業帶來強大的資料防護策略。圖2. ActiveProtect備份專用一體機,現可透過 Synology 全球官方合作夥伴和經銷商選購。欲了解更多ActiveProtect 備份專用一體機詳情或有任何需求, 歡迎至Synology群暉科技官網或聯繫hk.event@synology.com關於 Synology 群暉科技成立於 2000 年,Synology 專注於資料管理領域,提供資料儲存、備份、檔案協作、影像監控管理以及網路架構解決方案,目前在全球已累積超過 1000 萬名用戶,並在網路儲存設備 (NAS)專業使用者及企業市場取得領先地位。隨著資料成為各產業轉型核心,未來 Synology 將持續協助全球企業妥善管理、保護每一份資料,簡化 IT 管理流程。媒體聯繫窗口:Sandra Soh (Synology Regional Marketing)Email : sandrasoh@synology.com聯繫電話:+886 0905027104Andico Tsui (Senior Account Manager of SPRG)Email: andico.tsui@sprg.com.hk聯繫電話:+852 2114 4346 / 6902 3831 Copyright 2025 亞太商訊 via SeaPRwire.com.

Giftify, Inc. Launches Sports Ticket & Merchandise Savings Platform as Fan Expenses Surge

CardCash Platform Provides Cost-Reduction Strategy for High-Demand Sports Tickets and Merchandise Ahead of 2025 Major League Baseball (MLB) SeasonPlatform Supports Savings on Popular Sports Retailers Including StubHub, Nike, Adidas, Under Armour, Dick's Sporting Goods, and FanaticsSchaumburg, Illinois, Mar 5, 2025 - (ACN Newswire via SeaPRwire.com) - Giftify, Inc. (NASDAQ:GIFT) (the "Company"), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced the expansion of its CardCash.com platform into the high-margin sports retail sector, offering consumers smart saving solutions for sports fans to save on tickets, apparel and game-day essentials as part of the Company’s strategic growth initiative for 2025.With the 2025 MLB season getting underway, fans are facing rising costs for tickets, gear, and game-day essentials. The average cost of attending a baseball game has climbed to $152 for a family of four, with premium seats seeing increases as high as 38.8%. But CardCash.com, a leading secondary gift card exchange operated by Giftify, is stepping up to help fans save.By using discounted gift cards from StubHub, Nike, Adidas, Under Armour, Dick’s Sporting Goods, and Fanatics, families can cut costs on tickets, jerseys, and game-day snacks.For example, a family of four heading to a Yankees game this season, their tickets alone would cost over $300, but by paying with StubHub gift cards purchased at CardCash.com at an 11% discount, they save over $30. Grabbing team gear from MLB Shop? That's another 11% saved.Making Baseball More Affordable“With rising ticket prices, fans are looking for ways to save without missing out on their favorite teams,” said Carol Rosenblum, Marketing Manager at CardCash.com. “By using our discounted gift cards, baseball lovers can cut costs by 10-20%, whether they’re buying tickets, upgrading their game-day outfits, or picking up tailgating gear.”Spring Cleaning: Turn Unused Gift Cards into Game-Day CashThe CardCash.com platform offers a comprehensive solution for sports fans: not only can they purchase discounted gift cards to save on upcoming expenses, but they can also monetize unused gift cards by exchanging them for cash or store credit—creating a complete financial ecosystem for sports enthusiasts. Just as fans engage in spring cleaning around their homes, CardCash encourages them to clear out their wallets and drawers of forgotten gift cards and transform that untapped value into memorable sports experiences.“As MLB teams welcome fans back to stadiums across the nation, this is the perfect time for people to check their wallets, trade in unused gift cards, and put those funds toward experiences they’ll actually enjoy,” said Ketan Thakker, CEO of Giftify, Inc. “Why let old gift cards go to waste when they can help get you to the ballpark? This sports fan initiative represents a key component of our 2025 growth strategy to penetrate high-frequency consumer spending categories while building recurring engagement with our platform.”About Giftify, Inc.Giftify, Inc. is a pioneer in the incentive and rewards industry with a focus on retail, dining & entertainment experiences, as the owner and operator of leading digital platforms, CardCash.com and Restaurant.com. CardCash.com is a leading secondary gift card exchange platform, allowing consumers and retailers to realize value by buying and selling gift cards at various scales. Its Restaurant.com is the nation’s largest restaurant-focused digital deals brand. Restaurant.com and our Corporate Incentives division connect digital consumers, businesses and communities offering thousands of dining, retail and entertainment deals options nationwide at over 184,000 restaurants and retailers. Restaurant.com prides itself on offering the best deal, every meal. Our gift cards and restaurant certificates allow customers to save at thousands of restaurants across the country with just a few clicks.For more information, visit: www.giftifyinc.com and www.cardcash.com and https://www.restaurant.com.Forward-Looking StatementsPress Releases may include forward-looking statements. In particular, the words “believe,” “may,” “could,” “should,” “expect,” “anticipate,” “estimate,” “project," "propose," "plan," "intend," and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company. Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Giftify, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Giftify, Inc. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company’s ability identify a suitable business model for the corporation.Investors Contacts:IR@giftifyinc.com Copyright 2025 ACN Newswire via SeaPRwire.com.